<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoXBRL; Version: 3.3b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: augt_10Qxbrl.xfr; Date: 2013/01/08T21:35:57 -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<xbrli:xbrl xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2012-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:us-gaap="http://fasb.org/us-gaap/2012-01-31" xmlns:us-roles="http://fasb.org/us-roles/2012-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2012-01-31" xmlns:augt="http://augme.com/20121130">
    <link:schemaRef xlink:href="augt-20121130.xsd" xlink:type="simple" />
    <xbrli:context id="From2011-09-01to2011-11-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137204</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2011-09-01</xbrli:startDate>
        <xbrli:endDate>2011-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-09-01to2012-11-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137204</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-09-01</xbrli:startDate>
        <xbrli:endDate>2012-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="D2012Q2YTD">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137204</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2011-03-01</xbrli:startDate>
        <xbrli:endDate>2011-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="D2013Q2YTD">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137204</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-03-01</xbrli:startDate>
        <xbrli:endDate>2012-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="I2012">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137204</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-02-29</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="I2013Q2">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137204</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-11-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="I2012_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137204</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-02-29</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="I2012_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137204</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-02-29</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="I2012_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137204</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-02-29</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="I2011">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137204</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2011-02-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-01-07">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137204</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-01-07</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="I2012_StockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137204</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-02-29</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="D2013Q2YTD_HipcricketIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137204</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">augt:HipcricketIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-03-01</xbrli:startDate>
        <xbrli:endDate>2012-08-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-11-30_TradeNamesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137204</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-11-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-11-30_NoncompeteAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137204</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-11-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-11-30_SoftwareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137204</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:SoftwareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-11-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-11-30_CustomerRelationshipsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137204</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-11-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-11-30_AcquiredTechnologyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137204</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">augt:AcquiredTechnologyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-11-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-11-30_PatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137204</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-11-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-11-30_PatentLitigationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137204</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">augt:PatentLitigationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-11-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-03-01to2012-11-30_CustomerRelationshipsMember_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137204</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-03-01</xbrli:startDate>
        <xbrli:endDate>2012-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-03-01to2012-11-30_TradeNamesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137204</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-03-01</xbrli:startDate>
        <xbrli:endDate>2012-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-03-01to2012-11-30_NoncompeteAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137204</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-03-01</xbrli:startDate>
        <xbrli:endDate>2012-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-03-01to2012-11-30_SoftwareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137204</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:SoftwareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-03-01</xbrli:startDate>
        <xbrli:endDate>2012-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-03-01to2012-11-30_CustomerRelationshipsMember_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137204</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-03-01</xbrli:startDate>
        <xbrli:endDate>2012-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-03-01to2012-11-30_AcquiredTechnologyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137204</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">augt:AcquiredTechnologyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-03-01</xbrli:startDate>
        <xbrli:endDate>2012-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-03-01to2012-11-30_PatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137204</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-03-01</xbrli:startDate>
        <xbrli:endDate>2012-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-03-01to2012-11-30_PatentLitigationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137204</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">augt:PatentLitigationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-03-01</xbrli:startDate>
        <xbrli:endDate>2012-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="D2012_TradeNamesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137204</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2011-03-01</xbrli:startDate>
        <xbrli:endDate>2012-02-29</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="D2012_NoncompeteAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137204</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2011-03-01</xbrli:startDate>
        <xbrli:endDate>2012-02-29</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="D2012_SoftwareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137204</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:SoftwareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2011-03-01</xbrli:startDate>
        <xbrli:endDate>2012-02-29</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="D2012_CustomerRelationshipsMember_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137204</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2011-03-01</xbrli:startDate>
        <xbrli:endDate>2012-02-29</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="D2012_CustomerRelationshipsMember_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137204</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2011-03-01</xbrli:startDate>
        <xbrli:endDate>2012-02-29</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="D2012_AcquiredTechnologyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137204</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">augt:AcquiredTechnologyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2011-03-01</xbrli:startDate>
        <xbrli:endDate>2012-02-29</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="D2012_PatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137204</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2011-03-01</xbrli:startDate>
        <xbrli:endDate>2012-02-29</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="D2012_PatentLitigationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137204</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">augt:PatentLitigationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2011-03-01</xbrli:startDate>
        <xbrli:endDate>2012-02-29</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="I2012_TradeNamesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137204</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-02-29</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="I2012_NoncompeteAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137204</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-02-29</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="I2012_SoftwareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137204</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:SoftwareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-02-29</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="I2012_CustomerRelationshipsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137204</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-02-29</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="I2012_AcquiredTechnologyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137204</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">augt:AcquiredTechnologyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-02-29</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="I2012_PatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137204</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-02-29</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="I2012_PatentLitigationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137204</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">augt:PatentLitigationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-02-29</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="I2013Q1_HipcricketIncMember_AcquisitionRelatedContingentConsiderationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137204</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">augt:HipcricketIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">augt:AcquisitionRelatedContingentConsiderationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="D2013Q1_HipcricketIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137204</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">augt:HipcricketIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-03-01</xbrli:startDate>
        <xbrli:endDate>2012-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2011-11-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137204</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2011-11-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-03-01to2012-11-30_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137204</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-03-01</xbrli:startDate>
        <xbrli:endDate>2012-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-11-30_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137204</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-11-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-03-01to2012-11-30_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137204</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-03-01</xbrli:startDate>
        <xbrli:endDate>2012-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-11-30_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137204</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-11-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-03-01to2012-11-30_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137204</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-03-01</xbrli:startDate>
        <xbrli:endDate>2012-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-11-30_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137204</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-11-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-02-29_TradeNameMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137204</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">augt:TradeNameMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-02-29</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-11-30_TradeNameMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137204</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">augt:TradeNameMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-11-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-03-01to2013-02-28">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137204</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-03-01</xbrli:startDate>
        <xbrli:endDate>2013-02-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-09-01to2012-11-30_CustomerOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137204</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">augt:CustomerOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-09-01</xbrli:startDate>
        <xbrli:endDate>2012-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-03-01to2012-11-30_CustomerOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137204</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">augt:CustomerOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-03-01</xbrli:startDate>
        <xbrli:endDate>2012-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-09-01to2012-11-30_CustomerTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137204</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">augt:CustomerTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-09-01</xbrli:startDate>
        <xbrli:endDate>2012-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-03-01to2012-11-30_CustomerTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137204</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">augt:CustomerTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-03-01</xbrli:startDate>
        <xbrli:endDate>2012-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-09-01to2012-11-30_CustomerThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137204</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">augt:CustomerThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-09-01</xbrli:startDate>
        <xbrli:endDate>2012-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2011-09-01to2011-11-30_ThreeCustomersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137204</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">augt:ThreeCustomersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2011-09-01</xbrli:startDate>
        <xbrli:endDate>2011-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2011-03-01to2011-11-30_ThreeCustomersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137204</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">augt:ThreeCustomersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2011-03-01</xbrli:startDate>
        <xbrli:endDate>2011-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-03-01to2012-11-30_NoOtherCustomers">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137204</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">augt:NoOtherCustomersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-03-01</xbrli:startDate>
        <xbrli:endDate>2012-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-09-01to2012-11-30_NoOtherCustomers">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137204</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">augt:NoOtherCustomersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-09-01</xbrli:startDate>
        <xbrli:endDate>2012-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-11-30_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137204</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-11-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-02-29_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137204</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-02-29</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-11-30_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137204</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-11-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-02-29_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137204</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-02-29</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-08-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137204</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-08-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-03-01to2012-11-30_GeosCommunicationsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137204</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">augt:GeosCommunicationsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-03-01</xbrli:startDate>
        <xbrli:endDate>2012-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-03-01to2012-11-30_HipcricketIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137204</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">augt:HipcricketIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-03-01</xbrli:startDate>
        <xbrli:endDate>2012-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-03-01to2012-11-30_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137204</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-03-01</xbrli:startDate>
        <xbrli:endDate>2012-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-03-01to2012-11-30_StockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137204</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-03-01</xbrli:startDate>
        <xbrli:endDate>2012-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-09-01to2012-11-30_StockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137204</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-09-01</xbrli:startDate>
        <xbrli:endDate>2012-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2011-09-01to2011-11-30_StockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137204</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2011-09-01</xbrli:startDate>
        <xbrli:endDate>2011-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-03-01to2012-11-30_StockOptionsMember11985712">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137204</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-03-01</xbrli:startDate>
        <xbrli:endDate>2012-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2011-03-01to2011-11-30_StockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137204</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2011-03-01</xbrli:startDate>
        <xbrli:endDate>2011-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-09-01to2012-11-30_SellingAndMarketingExpenseMember_StockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137204</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-09-01</xbrli:startDate>
        <xbrli:endDate>2012-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2011-09-01to2011-11-30_SellingAndMarketingExpenseMember_StockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137204</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2011-09-01</xbrli:startDate>
        <xbrli:endDate>2011-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-03-01to2012-11-30_SellingAndMarketingExpenseMember_StockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137204</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-03-01</xbrli:startDate>
        <xbrli:endDate>2012-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2011-03-01to2011-11-30_SellingAndMarketingExpenseMember_StockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137204</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2011-03-01</xbrli:startDate>
        <xbrli:endDate>2011-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-09-01to2012-11-30_TechnologyAndDevelopmentMember_StockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137204</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis">augt:TechnologyAndDevelopmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-09-01</xbrli:startDate>
        <xbrli:endDate>2012-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2011-09-01to2011-11-30_TechnologyAndDevelopmentMember_StockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137204</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis">augt:TechnologyAndDevelopmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2011-09-01</xbrli:startDate>
        <xbrli:endDate>2011-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-03-01to2012-11-30_TechnologyAndDevelopmentMember_StockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137204</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis">augt:TechnologyAndDevelopmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-03-01</xbrli:startDate>
        <xbrli:endDate>2012-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2011-03-01to2011-11-30_TechnologyAndDevelopmentMember_StockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137204</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis">augt:TechnologyAndDevelopmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2011-03-01</xbrli:startDate>
        <xbrli:endDate>2011-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-09-01to2012-11-30_GeneralAndAdministrativeExpenseMember_StockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137204</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-09-01</xbrli:startDate>
        <xbrli:endDate>2012-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2011-09-01to2011-11-30_GeneralAndAdministrativeExpenseMember_StockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137204</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2011-09-01</xbrli:startDate>
        <xbrli:endDate>2011-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-03-01to2012-11-30_GeneralAndAdministrativeExpenseMember_StockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137204</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-03-01</xbrli:startDate>
        <xbrli:endDate>2012-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2011-03-01to2011-11-30_GeneralAndAdministrativeExpenseMember_StockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137204</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2011-03-01</xbrli:startDate>
        <xbrli:endDate>2011-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-11-30_StockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137204</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-11-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-09-01to2012-11-30_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137204</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-09-01</xbrli:startDate>
        <xbrli:endDate>2012-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2011-09-01to2011-11-30_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137204</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2011-09-01</xbrli:startDate>
        <xbrli:endDate>2011-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-03-01to2012-11-30_WarrantMember11985712">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137204</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-03-01</xbrli:startDate>
        <xbrli:endDate>2012-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2011-03-01to2011-11-30_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137204</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2011-03-01</xbrli:startDate>
        <xbrli:endDate>2011-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-02-29_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137204</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-02-29</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-11-30_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001137204</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-11-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Item">
      <xbrli:measure>augt:item</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPerShare">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Integer">
      <xbrli:measure>augt:Integer</xbrli:measure>
    </xbrli:unit>
    <dei:EntityRegistrantName contextRef="D2013Q2YTD">Augme Technologies, Inc.</dei:EntityRegistrantName>
    <dei:EntityCentralIndexKey contextRef="D2013Q2YTD">0001137204</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="D2013Q2YTD">10-Q</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="D2013Q2YTD">2012-11-30</dei:DocumentPeriodEndDate>
    <dei:AmendmentFlag contextRef="D2013Q2YTD">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="D2013Q2YTD">--02-28</dei:CurrentFiscalYearEndDate>
    <dei:EntityCurrentReportingStatus contextRef="D2013Q2YTD">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityFilerCategory contextRef="D2013Q2YTD">Accelerated Filer</dei:EntityFilerCategory>
    <dei:DocumentFiscalYearFocus contextRef="D2013Q2YTD">2013</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="D2013Q2YTD">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2013-01-07" unitRef="Shares" decimals="INF">116020847</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityPublicFloat contextRef="AsOf2013-01-07" unitRef="USD" decimals="0">11602</dei:EntityPublicFloat>
    <us-gaap:Assets contextRef="I2012" unitRef="USD" decimals="0">100592076</us-gaap:Assets>
    <us-gaap:Assets contextRef="I2013Q2" unitRef="USD" decimals="0">90274094</us-gaap:Assets>
    <us-gaap:DepositsAssetsNoncurrent contextRef="I2012" unitRef="USD" decimals="0">365700</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:DepositsAssetsNoncurrent contextRef="I2013Q2" unitRef="USD" decimals="0">239511</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="I2012" unitRef="USD" decimals="0">36798085</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="I2013Q2" unitRef="USD" decimals="0">30489139</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill contextRef="I2012" unitRef="USD" decimals="0">47484708</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="I2013Q2" unitRef="USD" decimals="0">47484708</us-gaap:Goodwill>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="I2012" unitRef="USD" decimals="0">292492</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="I2013Q2" unitRef="USD" decimals="0">128772</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:AssetsCurrent contextRef="I2012" unitRef="USD" decimals="0">15651091</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="I2013Q2" unitRef="USD" decimals="0">11931964</us-gaap:AssetsCurrent>
    <us-gaap:AssetsHeldForSaleCurrent contextRef="I2012" unitRef="USD" xsi:nil="true" />
    <us-gaap:AssetsHeldForSaleCurrent contextRef="I2013Q2" unitRef="USD" decimals="0">3500000</us-gaap:AssetsHeldForSaleCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="I2012" unitRef="USD" decimals="0">487321</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="I2013Q2" unitRef="USD" decimals="0">555689</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="I2012" unitRef="USD" decimals="0">3734945</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="I2013Q2" unitRef="USD" decimals="0">6112742</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="I2012" unitRef="USD" decimals="0">11428825</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="I2013Q2" unitRef="USD" decimals="0">1763533</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="I2011" unitRef="USD" decimals="0">11182356</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2011-11-30" unitRef="USD" decimals="0">16947363</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:DeferredRevenueCurrent contextRef="I2012" unitRef="USD" decimals="0">1050369</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueCurrent contextRef="I2013Q2" unitRef="USD" decimals="0">1181556</us-gaap:DeferredRevenueCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="I2012" unitRef="USD" decimals="0">1599792</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="I2013Q2" unitRef="USD" decimals="0">3017532</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="I2012" unitRef="USD" decimals="0">2613238</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="I2013Q2" unitRef="USD" decimals="0">4566076</us-gaap:AccountsPayableCurrent>
    <us-gaap:ShortTermBorrowings contextRef="I2012" unitRef="USD" xsi:nil="true" />
    <us-gaap:ShortTermBorrowings contextRef="I2013Q2" unitRef="USD" decimals="0">236161</us-gaap:ShortTermBorrowings>
    <us-gaap:LiabilitiesCurrent contextRef="I2012" unitRef="USD" decimals="0">31263899</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="I2013Q2" unitRef="USD" decimals="0">9040986</us-gaap:LiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesNoncurrent contextRef="I2012" unitRef="USD" decimals="0">113277</us-gaap:AccountsPayableAndAccruedLiabilitiesNoncurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesNoncurrent contextRef="I2013Q2" unitRef="USD" decimals="0">56726</us-gaap:AccountsPayableAndAccruedLiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="I2012" unitRef="USD" decimals="0">31377176</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="I2013Q2" unitRef="USD" decimals="0">9097712</us-gaap:Liabilities>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="I2012" unitRef="USD" decimals="0">100592076</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="I2013Q2" unitRef="USD" decimals="0">90274094</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="I2012" unitRef="USD" decimals="0">69214900</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="I2013Q2" unitRef="USD" decimals="0">81176382</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="I2012_CommonStockMember" unitRef="USD" decimals="0">9443</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="I2012_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">141738528</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="I2012_RetainedEarningsMember" unitRef="USD" decimals="0">-72533071</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2012-11-30_CommonStockMember" unitRef="USD" decimals="0">11605</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2012-11-30_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">168526789</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2012-11-30_RetainedEarningsMember" unitRef="USD" decimals="0">-87362012</us-gaap:StockholdersEquity>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="I2012" unitRef="USD" decimals="0">141738528</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="I2013Q2" unitRef="USD" decimals="0">168526789</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:CommonStockValue contextRef="I2012" unitRef="USD" decimals="0">9443</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="I2013Q2" unitRef="USD" decimals="0">11605</us-gaap:CommonStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="I2012" unitRef="USDPerShare" decimals="INF">.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="I2012" unitRef="Shares" decimals="INF">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="I2013Q2" unitRef="Shares" decimals="INF">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="I2012" unitRef="Shares" decimals="INF">94434817</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="I2013Q2" unitRef="Shares" decimals="INF">116054565</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="I2012" unitRef="Shares" decimals="INF">94434817</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="I2013Q2" unitRef="Shares" decimals="INF">116054565</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="From2011-09-01to2011-11-30" unitRef="USD" decimals="0">-11377289</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="From2012-09-01to2012-11-30" unitRef="USD" decimals="0">-4968347</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="D2012Q2YTD" unitRef="USD" decimals="0">-21398282</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="D2013Q2YTD" unitRef="USD" decimals="0">-14828941</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:AccretionExpense contextRef="From2011-09-01to2011-11-30" unitRef="USD" decimals="0">966750</us-gaap:AccretionExpense>
    <us-gaap:AccretionExpense contextRef="From2012-09-01to2012-11-30" unitRef="USD" decimals="0">-7339173</us-gaap:AccretionExpense>
    <us-gaap:AccretionExpense contextRef="D2012Q2YTD" unitRef="USD" decimals="0">966750</us-gaap:AccretionExpense>
    <us-gaap:AccretionExpense contextRef="D2013Q2YTD" unitRef="USD" decimals="0">-12199730</us-gaap:AccretionExpense>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="From2011-09-01to2011-11-30" unitRef="USD" decimals="0">2093</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="From2012-09-01to2012-11-30" unitRef="USD" decimals="0">-39856</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="D2012Q2YTD" unitRef="USD" decimals="0">21623</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="D2013Q2YTD" unitRef="USD" decimals="0">-36987</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:OperatingExpenses contextRef="From2011-09-01to2011-11-30" unitRef="USD" decimals="0">13436514</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2012-09-01to2012-11-30" unitRef="USD" decimals="0">16646503</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="D2012Q2YTD" unitRef="USD" decimals="0">25194666</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="D2013Q2YTD" unitRef="USD" decimals="0">38227857</us-gaap:OperatingExpenses>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill contextRef="From2011-09-01to2011-11-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill contextRef="From2012-09-01to2012-11-30" unitRef="USD" decimals="0">5849160</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill contextRef="D2012Q2YTD" unitRef="USD" xsi:nil="true" />
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill contextRef="D2013Q2YTD" unitRef="USD" decimals="0">5849160</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="From2011-09-01to2011-11-30" unitRef="USD" decimals="0">1236520</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="From2012-09-01to2012-11-30" unitRef="USD" decimals="0">1597443</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="D2012Q2YTD" unitRef="USD" decimals="0">1789776</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="D2013Q2YTD" unitRef="USD" decimals="0">4681129</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2011-09-01to2011-11-30" unitRef="USD" decimals="0">6700203</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2012-09-01to2012-11-30" unitRef="USD" decimals="0">3457777</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="D2012Q2YTD" unitRef="USD" decimals="0">13589610</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="D2013Q2YTD" unitRef="USD" decimals="0">10441082</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2011-09-01to2011-11-30" unitRef="USD" decimals="0">1765199</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2012-09-01to2012-11-30" unitRef="USD" decimals="0">1927193</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="D2012Q2YTD" unitRef="USD" decimals="0">3023023</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="D2013Q2YTD" unitRef="USD" decimals="0">5937333</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingAndMarketingExpense contextRef="From2011-09-01to2011-11-30" unitRef="USD" decimals="0">3734592</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense contextRef="From2012-09-01to2012-11-30" unitRef="USD" decimals="0">3814930</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense contextRef="D2012Q2YTD" unitRef="USD" decimals="0">6792257</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense contextRef="D2013Q2YTD" unitRef="USD" decimals="0">11319153</us-gaap:SellingAndMarketingExpense>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="From2011-09-01to2011-11-30" unitRef="USD" decimals="0">1400658</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="From2012-09-01to2012-11-30" unitRef="USD" decimals="0">3054212</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="D2012Q2YTD" unitRef="USD" decimals="0">2175937</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="D2013Q2YTD" unitRef="USD" decimals="0">7464449</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:SalesRevenueNet contextRef="From2011-09-01to2011-11-30" unitRef="USD" decimals="0">4424540</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="From2012-09-01to2012-11-30" unitRef="USD" decimals="0">7433051</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="D2012Q2YTD" unitRef="USD" decimals="0">6917448</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="D2013Q2YTD" unitRef="USD" decimals="0">18700622</us-gaap:SalesRevenueNet>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2011-09-01to2011-11-30" unitRef="Shares" decimals="INF">84758161</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2012-09-01to2012-11-30" unitRef="Shares" decimals="INF">108460588</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="D2012Q2YTD" unitRef="Shares" decimals="INF">70422761</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="D2013Q2YTD" unitRef="Shares" decimals="INF">99718225</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2011-09-01to2011-11-30" unitRef="USDPerShare" decimals="INF">-0.13</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2012-09-01to2012-11-30" unitRef="USDPerShare" decimals="INF">-0.05</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="D2012Q2YTD" unitRef="USDPerShare" decimals="INF">-0.30</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="D2013Q2YTD" unitRef="USDPerShare" decimals="INF">-0.15</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:OperatingIncomeLoss contextRef="From2011-09-01to2011-11-30" unitRef="USD" decimals="0">-10412632</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2012-09-01to2012-11-30" unitRef="USD" decimals="0">-12267664</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="D2012Q2YTD" unitRef="USD" decimals="0">-20453155</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="D2013Q2YTD" unitRef="USD" decimals="0">-26991684</us-gaap:OperatingIncomeLoss>
    <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="D2012Q2YTD" unitRef="USD" decimals="0">-10052105</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="D2013Q2YTD" unitRef="USD" decimals="0">-10408628</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities contextRef="D2012Q2YTD" unitRef="USD" xsi:nil="true" />
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities contextRef="D2013Q2YTD" unitRef="USD" decimals="0">-56551</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="D2012Q2YTD" unitRef="USD" decimals="0">-920321</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="D2013Q2YTD" unitRef="USD" decimals="0">131187</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="D2012Q2YTD" unitRef="USD" decimals="0">2400319</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="D2013Q2YTD" unitRef="USD" decimals="0">3370578</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInDepositOtherAssets contextRef="D2012Q2YTD" unitRef="USD" decimals="0">375509</us-gaap:IncreaseDecreaseInDepositOtherAssets>
    <us-gaap:IncreaseDecreaseInDepositOtherAssets contextRef="D2013Q2YTD" unitRef="USD" decimals="0">-126189</us-gaap:IncreaseDecreaseInDepositOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="D2012Q2YTD" unitRef="USD" decimals="0">107233</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="D2013Q2YTD" unitRef="USD" decimals="0">68368</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="D2012Q2YTD" unitRef="USD" decimals="0">-317622</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="D2013Q2YTD" unitRef="USD" decimals="0">2423366</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <augt:AcquisitionRelatedContingentExpense contextRef="D2012Q2YTD" unitRef="USD" decimals="0">966750</augt:AcquisitionRelatedContingentExpense>
    <augt:AcquisitionRelatedContingentExpense contextRef="D2013Q2YTD" unitRef="USD" decimals="0">-12199730</augt:AcquisitionRelatedContingentExpense>
    <augt:StockOptionAndWarrantExpense contextRef="D2012Q2YTD" unitRef="USD" decimals="0">7010288</augt:StockOptionAndWarrantExpense>
    <augt:StockOptionAndWarrantExpense contextRef="D2013Q2YTD" unitRef="USD" decimals="0">4302359</augt:StockOptionAndWarrantExpense>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="D2012Q2YTD" unitRef="USD" xsi:nil="true" />
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="D2013Q2YTD" unitRef="USD" decimals="0">-400</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="D2012Q2YTD" unitRef="USD" xsi:nil="true" />
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="D2013Q2YTD" unitRef="USD" decimals="0">625000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:AdjustmentOfWarrantsGrantedForServices contextRef="D2012Q2YTD" unitRef="USD" decimals="0">238990</us-gaap:AdjustmentOfWarrantsGrantedForServices>
    <us-gaap:AdjustmentOfWarrantsGrantedForServices contextRef="D2013Q2YTD" unitRef="USD" xsi:nil="true" />
    <us-gaap:OtherNoncashExpense contextRef="D2012Q2YTD" unitRef="USD" xsi:nil="true" />
    <us-gaap:OtherNoncashExpense contextRef="D2013Q2YTD" unitRef="USD" decimals="0">36757</us-gaap:OtherNoncashExpense>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="D2012Q2YTD" unitRef="USD" decimals="0">25495</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="D2013Q2YTD" unitRef="USD" decimals="0">45569</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="D2012Q2YTD" unitRef="USD" decimals="0">-5741753</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="D2013Q2YTD" unitRef="USD" decimals="0">-6926279</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
    <us-gaap:PaymentsToAcquireLongtermInvestments contextRef="D2012Q2YTD" unitRef="USD" xsi:nil="true" />
    <us-gaap:PaymentsToAcquireLongtermInvestments contextRef="D2013Q2YTD" unitRef="USD" decimals="0">200000</us-gaap:PaymentsToAcquireLongtermInvestments>
    <augt:PaymentOfAcquisitionRelatedContingentConsideration contextRef="D2012Q2YTD" unitRef="USD" xsi:nil="true" />
    <augt:PaymentOfAcquisitionRelatedContingentConsideration contextRef="D2013Q2YTD" unitRef="USD" decimals="INF">3182209</augt:PaymentOfAcquisitionRelatedContingentConsideration>
    <augt:PaymentOfAcquisitionRelatedContingentConsideration contextRef="D2013Q1_HipcricketIncMember" unitRef="USD" decimals="INF">200000</augt:PaymentOfAcquisitionRelatedContingentConsideration>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="D2012Q2YTD" unitRef="USD" decimals="0">3967794</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="D2013Q2YTD" unitRef="USD" xsi:nil="true" />
    <augt:PaymentsForCapitalizedPatentDefenseCosts contextRef="D2012Q2YTD" unitRef="USD" decimals="0">1716122</augt:PaymentsForCapitalizedPatentDefenseCosts>
    <augt:PaymentsForCapitalizedPatentDefenseCosts contextRef="D2013Q2YTD" unitRef="USD" decimals="0">2723931</augt:PaymentsForCapitalizedPatentDefenseCosts>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="D2012Q2YTD" unitRef="USD" decimals="0">63800</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="D2013Q2YTD" unitRef="USD" decimals="0">820139</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="D2012Q2YTD" unitRef="USD" decimals="0">5963</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="D2013Q2YTD" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="D2012Q2YTD" unitRef="USD" decimals="0">21558865</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="D2013Q2YTD" unitRef="USD" decimals="0">7669615</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
    <augt:ProceedsFromExerciseOfStockOptionsAndWarrants contextRef="D2012Q2YTD" unitRef="USD" decimals="0">2815813</augt:ProceedsFromExerciseOfStockOptionsAndWarrants>
    <augt:ProceedsFromExerciseOfStockOptionsAndWarrants contextRef="D2013Q2YTD" unitRef="USD" decimals="0">1257160</augt:ProceedsFromExerciseOfStockOptionsAndWarrants>
    <us-gaap:RepaymentsOfShortTermDebt contextRef="D2012Q2YTD" unitRef="USD" xsi:nil="true" />
    <us-gaap:RepaymentsOfShortTermDebt contextRef="D2013Q2YTD" unitRef="USD" decimals="0">200000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:ProceedsFromShortTermDebt contextRef="D2012Q2YTD" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProceedsFromShortTermDebt contextRef="D2013Q2YTD" unitRef="USD" decimals="0">450000</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="D2012Q2YTD" unitRef="USD" decimals="0">18743052</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="D2013Q2YTD" unitRef="USD" decimals="0">6162455</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInContinuingOperations contextRef="D2012Q2YTD" unitRef="USD" decimals="0">5765007</us-gaap:NetCashProvidedByUsedInContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInContinuingOperations contextRef="D2013Q2YTD" unitRef="USD" decimals="0">-9665292</us-gaap:NetCashProvidedByUsedInContinuingOperations>
    <us-gaap:InterestPaid contextRef="D2012Q2YTD" unitRef="USD" xsi:nil="true" />
    <us-gaap:InterestPaid contextRef="D2013Q2YTD" unitRef="USD" decimals="0">3100</us-gaap:InterestPaid>
    <augt:NoncashOrPartNoncashBusinessAcquisitionContingentConsideration contextRef="D2012Q2YTD" unitRef="USD" decimals="0">23284000</augt:NoncashOrPartNoncashBusinessAcquisitionContingentConsideration>
    <augt:NoncashOrPartNoncashBusinessAcquisitionContingentConsideration contextRef="D2013Q2YTD" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssued1 contextRef="D2012Q2YTD" unitRef="USD" decimals="0">41167889</us-gaap:StockIssued1>
    <us-gaap:StockIssued1 contextRef="D2013Q2YTD" unitRef="USD" xsi:nil="true" />
    <augt:AcquisitionRelatedContingentConsiderationSettledInStock contextRef="D2012Q2YTD" unitRef="USD" xsi:nil="true" />
    <augt:AcquisitionRelatedContingentConsiderationSettledInStock contextRef="D2013Q2YTD" unitRef="USD" decimals="0">10578900</augt:AcquisitionRelatedContingentConsiderationSettledInStock>
    <augt:NoncashOrPartNoncashStockIssuedForAcquisitionOfIntangibleAssets contextRef="D2012Q2YTD" unitRef="USD" xsi:nil="true" />
    <augt:NoncashOrPartNoncashStockIssuedForAcquisitionOfIntangibleAssets contextRef="D2013Q2YTD" unitRef="USD" decimals="0">3813953</augt:NoncashOrPartNoncashStockIssuedForAcquisitionOfIntangibleAssets>
    <us-gaap:SharesIssued contextRef="I2012_CommonStockMember" unitRef="Shares" decimals="INF">94434817</us-gaap:SharesIssued>
    <us-gaap:SharesIssued contextRef="AsOf2012-11-30_CommonStockMember" unitRef="Shares" decimals="INF">116054565</us-gaap:SharesIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="D2013Q2YTD" unitRef="USD" decimals="0">3679444</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="From2012-03-01to2012-11-30_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="From2012-03-01to2012-11-30_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">3679444</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="From2012-03-01to2012-11-30_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="D2013Q2YTD" unitRef="USD" decimals="0">625000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2012-03-01to2012-11-30_CommonStockMember" unitRef="USD" decimals="0">50</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2012-03-01to2012-11-30_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">624950</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2012-03-01to2012-11-30_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="D2013Q2YTD" unitRef="Shares" decimals="INF">500000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="From2012-03-01to2012-11-30_CommonStockMember" unitRef="Shares" decimals="INF">500000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <augt:WarrantsIssuedWithDebtIssuance contextRef="D2013Q2YTD" unitRef="USD" decimals="0">50596</augt:WarrantsIssuedWithDebtIssuance>
    <augt:WarrantsIssuedWithDebtIssuance contextRef="From2012-03-01to2012-11-30_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <augt:WarrantsIssuedWithDebtIssuance contextRef="From2012-03-01to2012-11-30_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">50596</augt:WarrantsIssuedWithDebtIssuance>
    <augt:WarrantsIssuedWithDebtIssuance contextRef="From2012-03-01to2012-11-30_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <augt:WarrantExpense contextRef="D2013Q2YTD" unitRef="USD" decimals="0">622915</augt:WarrantExpense>
    <augt:WarrantExpense contextRef="From2012-03-01to2012-11-30_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <augt:WarrantExpense contextRef="From2012-03-01to2012-11-30_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">622915</augt:WarrantExpense>
    <augt:WarrantExpense contextRef="From2012-03-01to2012-11-30_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="D2013Q2YTD" unitRef="USD" decimals="0">-14828941</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2012-03-01to2012-11-30_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2012-03-01to2012-11-30_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2012-03-01to2012-11-30_RetainedEarningsMember" unitRef="USD" decimals="0">-14828941</us-gaap:NetIncomeLoss>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="D2013Q2YTD" unitRef="USD" decimals="0">10578900</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="From2012-03-01to2012-11-30_CommonStockMember" unitRef="USD" decimals="0">923</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="From2012-03-01to2012-11-30_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">10577977</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="From2012-03-01to2012-11-30_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions contextRef="D2013Q2YTD" unitRef="Shares" decimals="INF">274997</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions contextRef="D2013Q2YTD_HipcricketIncMember" unitRef="Shares" decimals="INF">5225039</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions contextRef="D2013Q1_HipcricketIncMember" unitRef="Shares" decimals="INF">11457359</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions contextRef="From2012-03-01to2012-11-30_CommonStockMember" unitRef="Shares" decimals="INF">9234871</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions contextRef="From2012-03-01to2012-11-30_GeosCommunicationsIncMember" unitRef="Shares" decimals="INF">1.9</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions contextRef="From2012-03-01to2012-11-30_HipcricketIncMember" unitRef="Shares" decimals="INF">9.2</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets contextRef="D2013Q2YTD" unitRef="USD" decimals="0">3813953</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>
    <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets contextRef="From2012-03-01to2012-11-30_CommonStockMember" unitRef="USD" decimals="0">186</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>
    <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets contextRef="From2012-03-01to2012-11-30_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">3813767</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>
    <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets contextRef="From2012-03-01to2012-11-30_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets contextRef="From2012-03-01to2012-11-30_CommonStockMember" unitRef="Shares" decimals="INF">1860465</us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets>
    <augt:StockSubscriptionWithWarrantsNetAmount contextRef="D2013Q2YTD" unitRef="USD" decimals="0">6162455</augt:StockSubscriptionWithWarrantsNetAmount>
    <augt:StockSubscriptionWithWarrantsNetAmount contextRef="From2012-03-01to2012-11-30_CommonStockMember" unitRef="USD" decimals="0">850</augt:StockSubscriptionWithWarrantsNetAmount>
    <augt:StockSubscriptionWithWarrantsNetAmount contextRef="From2012-03-01to2012-11-30_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">6161605</augt:StockSubscriptionWithWarrantsNetAmount>
    <augt:StockSubscriptionWithWarrantsNetAmount contextRef="From2012-03-01to2012-11-30_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <augt:StockSubscriptionWithWarrantsNetShares contextRef="From2012-03-01to2012-11-30_CommonStockMember" unitRef="Shares" decimals="INF">8500000</augt:StockSubscriptionWithWarrantsNetShares>
    <augt:OptionWarrantExerciseAmount contextRef="D2013Q2YTD" unitRef="USD" decimals="0">1257160</augt:OptionWarrantExerciseAmount>
    <augt:OptionWarrantExerciseAmount contextRef="From2012-03-01to2012-11-30_CommonStockMember" unitRef="USD" decimals="0">140</augt:OptionWarrantExerciseAmount>
    <augt:OptionWarrantExerciseAmount contextRef="From2012-03-01to2012-11-30_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">1257020</augt:OptionWarrantExerciseAmount>
    <augt:OptionWarrantExerciseAmount contextRef="From2012-03-01to2012-11-30_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <augt:OptionWarrantExerciseShares contextRef="From2012-03-01to2012-11-30_CommonStockMember" unitRef="Shares" decimals="INF">1392092</augt:OptionWarrantExerciseShares>
    <augt:CashlessOptionExerciseAmount contextRef="D2013Q2YTD" unitRef="USD" xsi:nil="true" />
    <augt:CashlessOptionExerciseAmount contextRef="From2012-03-01to2012-11-30_CommonStockMember" unitRef="USD" decimals="0">13</augt:CashlessOptionExerciseAmount>
    <augt:CashlessOptionExerciseAmount contextRef="From2012-03-01to2012-11-30_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">-13</augt:CashlessOptionExerciseAmount>
    <augt:CashlessOptionExerciseAmount contextRef="From2012-03-01to2012-11-30_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <augt:CashlessOptionExerciseShares contextRef="From2012-03-01to2012-11-30_CommonStockMember" unitRef="Shares" decimals="INF">132320</augt:CashlessOptionExerciseShares>
    <us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock contextRef="D2013Q2YTD">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The accompanying unaudited interim financial statements&#13;of Augme Technologies,&amp;#160;Inc. (&amp;#147;Augme&amp;#148; or the &amp;#147;Company&amp;#148;) have been prepared in accordance with accounting&#13;principles generally accepted in the United States of America and the rules&amp;#160;of the Securities and Exchange Commission, and&#13;should be read in conjunction with the audited financial statements and notes thereto contained in Augme&amp;#146;s Annual Report&#13;on Form 10-K filed with the Securities and Exchange Commission (&amp;#147;SEC&amp;#148;).&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In the opinion of management, all adjustments,&#13;consisting of normal recurring adjustments, necessary for a fair presentation of financial position and the results of operations&#13;for the interim periods presented have been reflected herein.&amp;#160;The results of operations for the interim periods are not necessarily&#13;indicative of the results to be expected for the full year. Notes to the financial statements that would substantially duplicate&#13;the disclosures contained in the audited financial statements for the fiscal year ended February&amp;#160;29, 2012 as reported in the&#13;Company&amp;#146;s Annual Report on Form&amp;#160;10-K have been omitted.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left"&gt;&lt;b&gt;&lt;i&gt;Description of Business&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Augme provides mobile marketing and advertising&#13;technology and services, enabling brands, advertising agencies, media companies and enterprise clients to engage customers, drive&#13;loyalty and increase sales. Augme&amp;#146;s AD LIFE mobile marketing technology platform allows marketers, brands, and agencies the&#13;ability to plan, create, test, deploy, and track mobile marketing programs across every mobile channel. Through the use of Consumer&#13;Response Tags (&amp;#147;CRTs&amp;#148;) such as 2D codes, UPC codes, Short Message Services (&amp;#147;SMS&amp;#148;), and image recognition,&#13;AD LIFE facilitates consumer brand interaction and the ability to track and analyze campaign results. Using its own patented device-detection&#13;and proprietary mobile content adaptation software, AD LIFE solves the mobile marketing industry problem of disparate operating&#13;systems, device types, and on-screen mobile content rendering. Augme also provides business to consumer utilities including national&#13;mobile couponing solutions, strategic mobile healthcare tools, custom mobile application development and consumer data tracking&#13;and analytics.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Augme owns the &amp;#147;Method and System for Adding&#13;Function to a Webpage&amp;#148; portfolio of patents, which cover technical processes and methods that are believed to be a foundational&#13;component of behavioral targeting &amp;#151; the automatic provision of customized content to individuals based on information such&#13;as past web activity, personal preferences, geography, or demographic data. The Company&amp;#146;s patent portfolio includes thirteen&#13;issued patents and over 80 pending U.S. and foreign patent applications.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Augme operates under one reportable segment, is&#13;headquartered in New York City and maintains an operations facility near Seattle, Washington.&amp;#160;&amp;#160;Additionally, the Company&#13;maintains a presence in Atlanta, Tucson, Dallas, Chicago, Miami, San Francisco and Los Angeles.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left"&gt;&lt;b&gt;&lt;i&gt;Liquidity&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The financial statements have been prepared on&#13;a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of&#13;business. As of November 30, 2012 and February 29, 2012, the Company had accumulated deficits of $87.4 million and $72.5 million,&#13;respectively. The Company is subject to the risks and challenges associated with companies at a similar stage of development including&#13;dependence on key individuals, challenges related to the successful development and marketing of its products and services, the&#13;integration of business combinations, and competition from substitute products and services and larger companies with greater financial,&#13;technical management and marketing resources. As of November 30, 2012, the Company had working capital of $2.9 million, and cash&#13;and cash equivalents of $1.8 million. In order to fund existing operations for the remainder of fiscal 2013 and into fiscal 2014,&#13;the Company will need to raise additional cash through equity or debt financings, and/or sell certain strategic assets, such as&#13;its purchased technology or patent portfolio.&amp;#160;&amp;#160;There is no certainty that the Company has the ability to raise additional&#13;funds through debt or equity financings under terms acceptable to the Company, or that the Company has the ability to sell strategic&#13;assets, which, if a sale is completed, may adversely affect ongoing operations.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company operates in the mobile marketing industry&#13;and accordingly, can be affected by a variety of factors. For example, management of the Company believes that any of the following&#13;factors could have a significant negative effect on the Company&amp;#146;s future financial position, results of operations and cash&#13;flows: lack of cash and the ability to raise cash as and when needed; unanticipated fluctuations in quarterly operating results,&#13;adverse changes in the Company&amp;#146;s relationship with significant customers or failure to secure contracts with other customers,&#13;intense competition, failure to attract and retain key personnel, failure to protect intellectual property, decrease in the migration&#13;trends from traditional advertising methods to digital and mobile media and the inability to manage growth.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In September 2012, the Company adopted a restructuring&#13;plan which includes reducing the number of employees, slowing the pace of investments in our IP portfolio and minimizing variable&#13;expenses. The Company is restructuring overall corporate overhead expenses in order to focus our business around our mobile marketing&#13;and advertising technology and services. We intend to minimize cash spend while carefully investing our resources and protecting&#13;our strategic assets to strengthen our position in the mobile marketing and mobile advertising industry. We believe that the restructuring&#13;plan will improve cash flow by approximately $6.0 million on an annual basis.&amp;#160;&amp;#160;Cash used to pay for costs associated&#13;with one-time contract termination and termination benefits during the third quarter ended November 30, 2012 was $0.4 million.&#13;We expect to use additional cash of $0.4 million during the fourth quarter of fiscal 2013 for restructuring.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In September 2012, we borrowed a total of $450,000&#13;from two lenders. The loans were used for working capital. We borrowed&amp;#160;&amp;#160;$250,000 from one lender.&amp;#160;&amp;#160;This loan&#13;bears interest at the rate of 12% per year and is due to be paid on the earlier of the first anniversary of the loan, the closing&#13;of a financing transaction through which we raise gross proceeds of not less than $10 million, an event of default as defined in&#13;the promissory note or upon a change of control as defined in the promissory note. In addition, we issued a note payable in the&#13;amount of $200,000 to Ernest W. Purcell, a former director. This loan was paid in full in October 2012.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On October 3, 2012, we completed a public&#13;offering of our securities pursuant to which we sold 8.5 million shares of common stock registered on a Form S-3 registration&#13;statement at a price to the public of $0.80 per share. We also issued warrants to purchase an additional 2.125 million shares&#13;of common stock at an exercise price of $0.96 per share. We raised $6.2 million in proceeds, net of $0.6 million in costs related&#13;to the offering, leaving approximately $48.0 million of the $75.0 million registered on the Form S-3 registration statement, which&#13;we filed in June 2011. We intend to use the net proceeds from this offering for organic expansion in existing and new markets&#13;and for general corporate purposes.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The preparation of financial statements in&#13;conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that&#13;affect the amounts reported in the financial statements. We regularly evaluate estimates and judgments based on historical experience&#13;and other relevant facts and circumstances. Actual results could differ from those estimates. Significant estimates relate to&#13;fair value of assets acquired and liabilities assumed in business combinations, acquisition related contingent consideration,&#13;allowances for tax assets, the use of the Black-Scholes pricing model for valuing stock option and common stock warrant issuances,&#13;estimates of future cash flows used to evaluate impairment of long-lived assets, revenues earned from percentage of completion&#13;contracts and the period in which revenues should be recorded.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Reclassifications&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Certain reclassifications have been made to&#13;prior periods to conform to current reporting. The presentation of our Consolidated Statements of Operations has been adjusted&#13;for the reclassification of operating expenses to be presented in the following categories: sales and marketing, technology and&#13;development, general and administrative and depreciation and amortization.&amp;#160;&amp;#160;The operating expenses for the three and&#13;nine months ended November 30, 2011 have been reclassified accordingly.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Summary of Significant Accounting Policies&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The condensed consolidated financial statements&#13;have been prepared in accordance with accounting principles generally accepted in the United States of America and pursuant to&#13;the rules and regulations of the SEC. The same accounting policies are followed for preparing the quarterly and annual financial&#13;information unless otherwise disclosed in the notes below.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Goodwill&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company reviews goodwill for impairment annually&#13;as of the first day of its fourth fiscal quarter, generally December 1&lt;font style="font-size: 7pt"&gt;st&lt;/font&gt;, and whenever events&#13;or changes in circumstances indicate the carrying value of goodwill may not be recoverable. The goodwill impairment test involves&#13;a two-step process. In the first step, we compare the fair value of each reporting unit to its carrying value. If the fair value&#13;of the reporting unit exceeds its carrying value, goodwill is not impaired and no further testing is required. If the fair value&#13;of the reporting unit is less than the carrying value, the Company must perform the second step of the impairment test to measure&#13;the amount of impairment loss, if any. If the implied fair value of the reporting unit's goodwill is less than the carrying value,&#13;the difference is recorded as an impairment loss.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company estimates the fair value of its reporting&#13;units using a weighting of fair values derived most significantly from the income approach and, to a lesser extent, the market&#13;approach. Under the income approach, the Company calculates the fair value of a reporting unit based on the present value of estimated&#13;future cash flows. Cash flow projections are based on management's estimates of revenue growth rates and operating margins, taking&#13;into consideration industry and market conditions. The discount rate used is based on the weighted-average cost of capital adjusted&#13;for the relevant risk associated with business-specific characteristics and the uncertainty related to the business's ability to&#13;execute on the projected cash flows. The market approach estimates fair value based on market multiples of revenue and earnings&#13;derived from comparable publicly-traded companies with similar operating and investment characteristics as the reporting unit.&#13;The weighting of the fair value derived from the market approach ranges from 0% to 50% depending on the level of comparability&#13;of these publicly-traded companies to the reporting unit. When market comparables are not meaningful or not available, the Company&#13;may estimate the fair value of a reporting unit using only the income approach.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In order to assess the reasonableness of the calculated&#13;fair values of its reporting units, the Company also compares the sum of the reporting units' fair values to the Company&amp;#146;s&#13;market capitalization and calculates an implied control premium (the excess of the sum of the reporting units' fair values over&#13;the market capitalization). The Company evaluates the control premium by comparing it to control premiums of recent comparable&#13;market transactions. If the implied control premium is not reasonable in light of these recent transactions, the Company will reevaluate&#13;its fair value estimates of the reporting units by adjusting the discount rates and/or other assumptions. As a result, when there&#13;is a significant decline in the Company&amp;#146;s stock price, as occurred during fiscal 2012, this reevaluation could correlate&#13;to lower estimated fair values for certain or all of the Company&amp;#146;s reporting units.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;The Company has a single operating segment,&#13;however there two reporting units for purposes of its goodwill impairment assessment, and all of the recorded goodwill is attributed&#13;to the Mobile Marketing and Advertising reporting unit, which generates substantially all of the revenues and expenses of the&#13;Company.&amp;#160;&amp;#160;The second reporting unit represents the Intellectual Property reporting unit, which does not contain any&#13;attributed goodwill.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Recently Issued Accounting Standards&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In July 2012, the FASB issued ASU&amp;#160;2012-02,&#13;&amp;#147;Testing Indefinite-Lived Intangible Assets for Impairment.&amp;#148; ASU 2012-02 amends the guidance in ASC 350-30 on testing&#13;indefinite-lived intangible assets, other than goodwill, for impairment.&amp;#160;&amp;#160;Under ASU 2012-02, an entity has the option&#13;of performing a qualitative assessment of whether it is more likely than not that the fair value of an entity&amp;#146;s indefinite-lived&#13;intangible asset is less than its carrying amount before calculating the fair value of the asset. If the conclusion is that it&#13;is more likely than not that the fair value of an indefinite-lived intangible asset is less than its carrying amount, the company&#13;would be required to calculate the fair value of the asset. ASU 2012-02 is effective for annual and interim impairment tests performed&#13;for fiscal years beginning after September&amp;#160;15, 2012, with early adoption permitted. We early adopted this guidance as of August&#13;31, 2012 in connection with our interim impairment assessment and it did not have a material impact on our financial position,&#13;results of operations, or cash flows.&lt;/p&gt;</us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="D2013Q2YTD">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the nine months ended November 30, 2012,&#13;Augme issued 8.5 million shares of common stock in connection with a public offering, with proceeds of $6.2 million, net of $0.6&#13;million in costs related to the offering. These shares were issued at $0.80 per share, and were registered on an S-3 registration&#13;statement filed with the SEC which allows Augme to sell securities having a total value of up to $75.0 million.&amp;#160;&amp;#160;There&#13;is approximately $48.0 million in value of unsold securities remaining registered on the Form S-3.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the nine months ended November 30, 2012,&#13;Augme issued approximately 1.9 million shares of common stock in connection with the acquisition of all of the outstanding common&#13;stock and preferred stock of a company, the assets of which comprise patents and intellectual property.&amp;#160;&amp;#160;See Note 5.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the nine months ended November 30, 2012,&#13;Augme issued approximately 9.2 million shares of common stock as acquisition related contingent consideration in accordance with&#13;the Amended and Restated Purchase Agreement between Augme and Hipcricket, Inc.&amp;#160;&amp;#160;See Note 5.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the nine months ended November 30, 2012,&#13;Augme issued 500,000 shares of common stock to the Company&amp;#146;s legal counsel for services rendered to the Company related to&#13;corporate transactions and SEC reporting.&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="D2013Q2YTD">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;b&gt;&lt;i&gt;Stock-Based Compensation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Stock-based compensation cost is measured at the&#13;grant date based on the estimated fair value of the award. We use the Black-Scholes option pricing model to estimate the fair value&#13;of stock options and warrants. The determination of the fair value of stock-based awards on the date of grant using an option pricing&#13;model is affected by our stock price as well as assumptions regarding a number of complex and subjective variables. These variables&#13;include our expected stock price volatility over the expected term of the awards, actual and projected employee stock option exercise&#13;behaviors, a risk-free interest rate and any expected dividends.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;b&gt;OPTIONS:&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;The estimated fair values of our stock option&#13;awards were determined using the following weighted average assumptions:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Three&amp;#160;Months&amp;#160;Ended&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;November 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Nine&amp;#160;Months&amp;#160;Ended&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;November 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; font-weight: bold"&gt;2012&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; font-weight: bold"&gt;2011&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; font-weight: bold"&gt;2012&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; font-weight: bold"&gt;2011&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 52%; text-align: left"&gt;Expected dividends&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;Expected term (in years)&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;3.50&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;5&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;3.50&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;5&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: left"&gt;Weighted-average volatility&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;65.00&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;%&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;77.70&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;%&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;62.38&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;%&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;77.70&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;Risk-free rate&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0.43&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;%&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0.40&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;%&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0.44&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;%&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0.40&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;The effect on our results of operations of recording&#13;share-based compensation expense for the three and nine months ended November 30, 2012 and 2011 was as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Three&amp;#160;Months&amp;#160;Ended&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;November 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Nine&amp;#160;Months&amp;#160;Ended&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;November 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; font-weight: bold"&gt;2012&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; font-weight: bold"&gt;2011&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; font-weight: bold"&gt;2012&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; font-weight: bold"&gt;2011&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 52%; text-align: left"&gt;Selling and marketing&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right"&gt;379,756&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right"&gt;1,043,590&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right"&gt;1,407,393&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right"&gt;2,104,527&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;Technology and development&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;272,621&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;425,449&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;882,591&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;857,970&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: left"&gt;General and administrative&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;534,876&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;846,961&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;1,389,460&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;1,708,001&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 2.4pt; text-align: left"&gt;Total stock-based compensation expense&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;1,187,253&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;2,316,000&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;3,679,444&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;4,670,498&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company maintains stock incentive plans for&#13;its employees. The 2010 Stock Incentive Plan provides for the grant to employees, officers, directors and consultants of options,&#13;restricted shares, and other stock based awards to purchase up to an aggregate of 15,000,000 shares of the Company&amp;#146;s common&#13;stock. The stock based awards may consist of both incentive stock options and non-qualified options.&amp;#160;&amp;#160;The Company has&#13;granted 13,056,707 stock options and restricted shares under this plan as of November 30, 2012.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company has also issued non-qualified stock&#13;options to consultants and vendors for services provided, as well as employees, including officers, directors and consultants.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The summary of activity for Augme&amp;#146;s stock&#13;options is presented below:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Number&amp;#160;of&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Exercise&amp;#160;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Average Remaining Contractual Term&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;(In Years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 56%; text-align: left"&gt;Options outstanding at February&amp;#160;29, 2012&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;20,153,219&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;2.13&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 15%; text-align: right"&gt;3.81&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;Granted&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;2,850,268&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;1.48&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: left"&gt;Exercised&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;(572,092&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;)&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0.53&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: left"&gt;Forfeited, cancelled and expired&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;(3,964,603&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: left"&gt;)&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: right"&gt;2.41&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: left"&gt;Options outstanding at November 30, 2012&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;18,466,792&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;2.04&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;3.22&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: left"&gt;Options vested and expected to vest at November 30, 2012&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;17,570,483&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;2.03&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;3.18&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;Options exercisable at November 30, 2012&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;12,491,061&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;1.96&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;2.84&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of November 30, 2012, there was $4.8 million&#13;of unrecognized share-based payment expense, which is expected to be recognized over a weighted average period of approximately&#13;2.0 years.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The aggregate intrinsic value of the exercisable&#13;options at November 30, 2012 was $90,000. The aggregate intrinsic value was calculated based on the positive differences between&#13;the market value of the Company&amp;#146;s common stock on November 30, 2012 of $0.61 per share and the exercise prices of the exercisable&#13;options.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The exercise prices of options outstanding at&#13;November 30, 2012 ranged from $0.25 to $4.10.&amp;#160;&amp;#160;The weighted average fair value of options granted was $0.61 per option&#13;share for the nine months ended November 30, 2012.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The aggregate intrinsic value of options exercised&#13;during the nine months ended November 30, 2012 was $0.8 million. The intrinsic value is calculated as the difference between the&#13;market value on the date of exercise and the exercise price of the shares.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;b&gt;WARRANTS:&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The estimated fair values of our stock warrant&#13;awards issued to service providers and employees were determined using the following weighted average assumptions:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Three&amp;#160;Months&amp;#160;Ended&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;November 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Nine&amp;#160;Months&amp;#160;Ended&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;November 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; font-weight: bold"&gt;2012&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; font-weight: bold"&gt;2011&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; font-weight: bold"&gt;2012&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; font-weight: bold"&gt;2011&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 52%; text-align: left"&gt;Expected dividends&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;Term (in years)&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;5.00&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;3&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;4.75&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;3. 9&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: left"&gt;Weighted-average volatility&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;65.00&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;%&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;81.32&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;%&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;64.37&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;%&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;77.80&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;Risk-free rate&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0.62&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;%&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0.40&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;%&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0.59&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;%&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0.40&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: right"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The warrant expense for the three and nine months&#13;ended November 30, 2012 and 2011 is as follows, and is included in general and administrative expense:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Three&amp;#160;Months&amp;#160;Ended&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;November 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Nine&amp;#160;Months&amp;#160;Ended&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;November 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; font-weight: bold"&gt;2012&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; font-weight: bold"&gt;2011&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; font-weight: bold"&gt;2012&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; font-weight: bold"&gt;2011&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.4pt; text-align: left"&gt;Total warrant expense&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;188,849&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;1,193,943&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;622,915&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;2,339,790&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;The summary of activity for Augme&amp;#146;s warrants&#13;is presented below:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; font-weight: bold"&gt;Number&amp;#160;of&amp;#160;Warrants&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1.5pt solid"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Exercise&amp;#160;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; font-weight: bold"&gt;Average Remaining Contractual Term (In Years)&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 56%; text-align: left"&gt;Warrants outstanding at February&amp;#160;29, 2012&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;10,787,641&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;1.86&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 15%; text-align: right"&gt;2.99&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;Granted&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;3,187,499&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;1.17&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: left"&gt;Exercised&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;(1,000,000&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;)&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;1.00&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: left"&gt;Forfeited, cancelled and expired&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: right; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; font-weight: bold"&gt;&amp;#151;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: right; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: right; font-weight: bold"&gt;&amp;#151;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: left"&gt;Warrants outstanding at November 30, 2012&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;12,975,140&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;1.76&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;2.77&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: left"&gt;Warrants vested and expected to vest at November 30, 2012&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;12,932,640&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;1.76&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;2.76&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;Warrants exercisable and outstanding at November 30, 2012&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;12,312,642&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;1.76&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;2.69&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The aggregate intrinsic value of the exercisable&#13;warrants at November 30, 2012 was zero. The aggregate intrinsic value was calculated based on the positive differences between&#13;the market value of the Company&amp;#146;s common stock on November 30, 2012 of $0.61 per share and the exercise prices of the exercisable&#13;warrants.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The exercise prices of warrants outstanding at&#13;November 30, 2012 ranged from $0.90 to $4.00.&amp;#160;&amp;#160;The weighted average fair value of warrants granted was $0.43 per warrant&#13;share for the nine months ended November 30, 2012.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of November 30, 2012, there was $0.3 million&#13;of unrecognized share-based payment expense, which is expected to be recognized over a weighted average period of approximately&#13;2.2 years.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The aggregate intrinsic value of warrants exercised&#13;during the nine months ended November 30, 2012 was $0.6 million. The intrinsic value is calculated as the difference between the&#13;market value on the date of exercise and the exercise price of the shares.&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:EarningsPerShareTextBlock contextRef="D2013Q2YTD">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Basic net income per share is based on the weighted&#13;average number of common shares outstanding. Diluted net income per share is based on the weighted average number of common shares&#13;and common share equivalents outstanding. Common share equivalents included in the computation represent shares issuable upon assumed&#13;exercise of outstanding stock options and warrants except when the effect of their inclusion would be anti-dilutive. As of November&#13;30, 2012, there were potentially dilutive securities consisting of options exercisable to purchase 2.2 million shares of common&#13;stock, and no warrants exercisable. As the inclusion of these outstanding stock options would be anti-dilutive, they were excluded&#13;from the computation of loss per share.&amp;#160;&amp;#160;Accordingly, basic net loss per share and diluted net loss per share are identical&#13;for each of the periods presented in the accompanying statements of operations.&lt;font style="font-size: 8pt"&gt; &lt;/font&gt;&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:BusinessCombinationDisclosureTextBlock contextRef="D2013Q2YTD">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Acquisition of Hipcricket,&amp;#160;Inc. Assets&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On August&amp;#160;25, 2011, Augme completed its acquisition&#13;of the business and substantially all of the assets of Hipcricket, Inc. (&amp;#147;Hipcricket&amp;#148;) pursuant to the Amended and&#13;Restated Asset Purchase Agreement (the &amp;#147;Agreement&amp;#148;) dated August&amp;#160;25, 2011 between Augme and Hipcricket. The acquisition&#13;provides Augme with expanded mobile marketing solutions for consumer brands, agencies, pharmaceutical/health, and media companies.&#13;The Company accounted for the acquisition as a business combination. The results of Hipcricket&amp;#146;s operations have been included&#13;in the financial statements of the Company since the date of the acquisition.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The estimated fair value of the acquisition consideration&#13;was $62.8 million, which included $3.0 million in cash, $35.5 million in Augme&amp;#146;s common stock (11,457,359 shares at a price&#13;of $3.10), a $1.0 million promissory note, which has been subsequently paid off in cash, and $2.0 million of seller tax liabilities,&#13;which was paid during the quarter ended May 31, 2012. In addition, the transaction called for a twelve-month earn-out payment to&#13;Hipcricket shareholders and employees, which if achieved was estimated to be no less than $15.0 million and as high as $27.5 million.&#13;The earn-out period ended August 25, 2012. The amount of contingent consideration was based on the amount of revenue recognized&#13;in the earn-out period to be paid in Augme&amp;#146;s common stock or a combination of common stock and cash at Augme&amp;#146;s discretion,&#13;provided that the transaction remained a tax-free reorganization.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The contingent consideration recorded at the time&#13;of the acquisition was $23.3 million plus the seller tax liabilities of $2.0 million, resulting in an aggregate liability on the&#13;transaction date of $25.2 million. The tax liability of $2.0 million was paid during the quarter ended May 31, 2012. The contingent&#13;consideration is determined based upon the revenue recognized during the earn-out period, and is paid 50% to former Hipcricket&#13;shareholders and 50% to those former Hipcricket employees and employee-shareholders that became employees of Augme subsequent to&#13;the acquisition. Based on an evaluation of the factors surrounding the transaction and the terms of the purchase agreement, the&#13;amount due under the earn-out provisions is accounted for as acquisition consideration.&amp;#160;&amp;#160;We concluded that the contingent&#13;consideration to be paid to employees was a significant component of the transaction date valuation of the acquired business and&#13;the calculation of the contingent payment was based upon factors established at the date of the transaction to be paid upon meeting&#13;the established revenue criteria of the acquired business. The post transaction employment arrangements of the continuing employees&#13;are at market rates and the formula for determining the contingent consideration is consistent with the business valuation methodologies,&#13;based upon a multiplier of revenue recognized from the acquired business for the twelve month period following the business combination.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Pursuant to the terms of the Agreement, the earn-out&#13;period ended on August 25, 2012 and the contingent earn-out consideration was calculated to be $21,999,780. On August 25, 2012,&#13;the measurement date of the contingent consideration obligation, the Company recognized a gain of $2,000,538 resulting from the&#13;reduction of the liability as the actual consideration due pursuant to the terms of the Agreement was less than management&amp;#146;s&#13;previous estimates.&amp;#160;&amp;#160;The gain is included within other income on the statement of operations for the quarter ended August&#13;31, 2012.&amp;#160;&amp;#160;The Company paid the contingent consideration in both cash and common stock, as provided under the Agreement,&#13;in transactions occurring on August 25, 2012 and November 2, 2012 for substantially most of the outstanding liability.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As partial satisfaction of the contingent acquisition&#13;consideration obligation, Augme paid the former Hipcricket stockholders, representing approximately 50% of the outstanding contingent&#13;consideration liability, using shares of its common stock. Pursuant to the terms of the Agreement, the number of common shares&#13;issued was calculated using a $2.00 per share denominator, as the Company&amp;#146;s common stock price as calculated under the Agreement&#13;was below the $2.00 &amp;#147;floor&amp;#148; as stated in the Agreement. Accordingly, Augme issued, in lieu of cash, a total of 5,500,036&#13;shares of common stock in satisfaction of the contingent consideration totaling $10,999,890 owed to the former Hipcricket shareholders.&#13;A total of 5,225,039 shares of common stock were issued during the quarter ended August 31, 2012 and the remaining 274,997 shares&#13;were issued during the current quarter ended November 30, 2012. The market price of the common stock on August 25, 2012 was $1.48.&amp;#160;&amp;#160;The&#13;difference between the $2.00 per share price used to calculate the number of shares to be issued per the terms of the Agreement,&#13;and the actual price of the shares of $1.48 on the measurement date, resulted in a reduction in the acquisition consideration payment&#13;of $2,860,019 which amount was included within other income on the statement of operations.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On November 2, 2012, Augme issued 3,734,835 shares&#13;of its common stock as form of payment, net of tax withholding, for the remaining contingent earn-out consideration in accordance&#13;with the Agreement. On December 4, 2012, this amount was reduced by 27,322 shares to 3,707,513 shares. The difference between the&#13;$2.00 per share price used to calculate the number of shares to be issued per the terms of the Agreement, and the actual price&#13;of the shares of $0.65 on the measurement date, which is the date on which the Company issued the shares, resulted in a reduction&#13;in the acquisition consideration payment of $7,339,173 which amount was included within other income on the statement of operations.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following table presents the change in Level&amp;#160;3&#13;acquisition related contingent consideration liability measured on a recurring basis for the three months ended November 30, 2012:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;August 31,&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center; font-weight: bold"&gt;Cash and Stock Payments&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1.5pt solid"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;(Gain)&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;&amp;#160;Included in&amp;#160;Earnings&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center; font-weight: bold"&gt;November 30, 2012&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: left"&gt;Acquisition related contingent consideration&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;10,999,890&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;(3,621,056)&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;(7,339,173)&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 7pt"&gt;(1)&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;39,661&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 3%; text-align: left; font-size: 7pt"&gt;(1)&lt;/td&gt;&#13;    &lt;td style="width: 87%; text-align: left"&gt;Included in other income in the statements of operations.&lt;/td&gt;&#13;    &lt;td style="width: 8%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following table presents the change in Level&amp;#160;3&#13;acquisition related contingent consideration liability measured on a recurring basis for the nine months ended November 30, 2012:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;February 29,&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center; font-weight: bold"&gt;Cash and Stock Payments&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1.5pt solid"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;(Gain)&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;&amp;#160;Included in&amp;#160;Earnings&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center; font-weight: bold"&gt;November 30, 2012&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: left"&gt;Acquisition related contingent consideration&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;26,000,500&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;(13,761,109)&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;(12,199,730)&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 7pt"&gt;(1)&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;39,661&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 3%; text-align: left; font-size: 7pt"&gt;(1)&lt;/td&gt;&#13;    &lt;td style="width: 86%; text-align: left"&gt;Included in other income in the statements of operations.&lt;/td&gt;&#13;    &lt;td style="width: 7%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;b&gt;&lt;i&gt;Unaudited Pro-Forma Results of Operations&#13;for Hipcricket Acquisition&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The results of this acquisition are included in&#13;the financial statements from the date of acquisition. The unaudited pro-forma results of operations data are being furnished solely&#13;for informational purposes and are not intended to represent or be indicative of the results of operations that we would have reported&#13;had the Hipcricket acquisition been completed at the beginning of the fiscal periods presented, nor are they necessarily indicative&#13;of future results. Pro-forma results include the discount of the present value of the contingent consideration over the period&#13;presented. The pro-forma results of operations for the nine months ended November 30, 2011 are as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; font-weight: bold"&gt;Nine Months Ended November 30, 2011&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 82%; text-align: left"&gt;Revenues&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 15%; text-align: right"&gt;11,851,321&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;Net loss&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;(21,985,225&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: left"&gt;Weighted average common shares&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;82,905,010&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;Basic and diluted net loss per share&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;(0.27&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160; &lt;/font&gt;&lt;b&gt;&lt;i&gt;Asset&#13;Acquisition &amp;#150; Patents and Intellectual Property&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On May 24, 2012, the Company acquired all of the&#13;common stock and all of the preferred stock of Geos Communications IP Holdings, Inc. (&amp;#147;Geos IP&amp;#148;).&amp;#160;&amp;#160;By acquiring&#13;the Geos IP stock, the Company acquired 5 U. S. patents covering Voice over Internet Protocol (&amp;#147;VoIP&amp;#148;) and other mobility&#13;inventions and 7 U.S. patent applications and 18 pending international patent applications covering related invention families&#13;within the field of mobile VoIP. The patents allow the Company to expand its mobile marketing and mobile advertising technology&#13;offerings to include adaptive voice technologies for any mobile environment, VoIP-enabled mobile marketing and advertising, VoIP-enabled&#13;e-commerce and VoIP-enabled services and support features within the Company&amp;#146;s AD LIFE mobile marketing and mobile advertising&#13;platform.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company determined that the Geos IP assets&#13;acquired did not constitute a business as defined under ASC Topic 805 on the basis that the Geos IP assets were not an integrated&#13;set of activities or assets that were capable of being conducted or managed in a manner that would provide economic benefits or&#13;return to the Company.&amp;#160;&amp;#160;As a result, the Company accounted for this acquisition as an asset purchase.&amp;#160;&amp;#160;The&#13;total consideration paid has been allocated to the intangible assets acquired based upon their relative fair values at the date&#13;of acquisition.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The fair value of the consideration given for&#13;the acquisition of the Geos IP stock was $4.2 million, which included $355,000 in cash and $3.8 million in Augme&amp;#146;s common&#13;stock (1,860,465 shares at a price of $2.05 per share). The Company is indemnified against certain losses resulting from breaches&#13;of any representation, warranty, covenant or agreement of Geos IP. In order to secure payment of any loss, the approximate 1.9&#13;million shares of Augme&amp;#146;s common stock will be held for the benefit of the sellers in escrow for a period of up to 14 months&#13;following the closing date of the acquisition. See Note 9 for details regarding the direct and indirect material interest of key&#13;management personnel in the acquisition. During the period ended November 30, 2012, the Company recognized an impairment write-down&#13;of the acquired Geos IP and the IP acquired from JAGTAG.&amp;#160;&amp;#160;See Note 7.&lt;/p&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock contextRef="D2013Q2YTD">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During period ended November 30 2012, the&#13;Company determined that sufficient indicators of potential impairment existed to require an interim goodwill impairment&#13;analysis for the  Mobile Marketing and Advertising reporting unit, the only reporting which has allocated goodwill.&#13;These indicators included the recent trading values of the Company&amp;#146;s stock, coupled with market conditions, recurring&#13;losses and the restructuring undertaken during the period. Upon completion of our initial qualitative assessment, we could&#13;not conclude that it was more likely than not that the fair value of the Mobile Marketing and Advertising reporting unit was&#13;more than the carrying amount, and therefore we performed the first step of the two-step process for evaluating the&#13;recoverability of recorded goodwill. The first step of this interim period goodwill impairment assessment compared the fair&#13;value of the related reporting unit with its carrying amount, including goodwill. The result of the first step of the&#13;Company&amp;#146;s interim period assessment of the recoverability of goodwill did not result in an indication of&#13;impairment.&amp;#160;&amp;#160;As such, step two was not completed and no impairment charge related to goodwill has been recorded&#13;during the period.&amp;#160;&amp;#160;The fair value of the Mobile Marketing and Advertising reporting unit was based on the income approach and the&#13;market approach.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Prior to completing the goodwill impairment test,&#13;the Company tested the recoverability of the Mobile Marketing and Advertising reporting unit long-lived assets (other than goodwill)&#13;and concluded that such assets were not impaired for this reporting unit. The Company also performed a test of the recoverability&#13;of the Intellectual Property Holding (&amp;#147;IP Holding&amp;#148;) reporting unit, which resulted in an impairment of long-lived intangible&#13;assets (see Note 7).&amp;#160;&amp;#160;However, no goodwill is allocated to the IP Holding reporting unit.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The result of the interim period impairment test&#13;did not result in an indication of impairment.&amp;#160;&amp;#160;However, any further reductions in the assessed fair value of the reporting&#13;unit greater than approximately 8 - 12%, or a deterioration of the related fair value inputs, would likely result in an impairment&#13;charge in the period of such assessment.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company will perform its annual impairment&#13;test during the fourth quarter.&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="D2013Q2YTD">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;b&gt;&lt;i&gt;Impairment of Patents&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Our intangible assets are reviewed for recoverability&#13;whenever an event or change in circumstance indicates that the carrying amount of such intangible asset or group of intangible&#13;assets may not be recoverable. As a result of efforts undertaken in the third quarter to market certain patents for sale, and as&#13;a result of the interim period goodwill impairment assessment (see Note 6), management concluded that a triggering event has occurred&#13;requiring us to assess whether the carrying amount of certain of our intellectual property assets is recoverable.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Identified intangible assets are included in both&#13;reporting units of our single operating segment, however the intellectual property for which indications of impairment existed&#13;are included in the IP Holding reporting unit, and those assets that were identified as&amp;#160;&amp;#160;impaired amounted to a net carrying&#13;value of $9.3 million prior to the impairment write-down.&amp;#160;&amp;#160;In conducting an impairment review of the intangible assets,&#13;the Company compares the fair value of the asset to its carrying value. If the fair value of the asset is less than the carrying&#13;value, the difference is recorded as an impairment loss. The Company estimated the fair value of the patents subject to the impairment&#13;analysis by calculating the expected proceeds to be received through a sale, exclusive license agreement and royalties that would&#13;have been paid to a third party had the Company not owned the patents. The expected proceeds to be received through a sale did&#13;not include an estimate of contingent fees to be received by the company related to participating in future licensing fees received&#13;by a purchaser, if any, under future settlement or royalty arrangements in which they pursue.&amp;#160;&amp;#160;Such fees are considered&#13;contingent gains and will be recognized when earned.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Following the completion of that analysis, the&#13;Company determined that the fair value of the patents acquired in the Geos IP asset acquisition and the JAGTAG business combination,&#13;which are not core to the ongoing business operations or utilized in any material manner by the Mobile Marketing and Advertising&#13;reporting unit, were less than the carrying value due primarily to the reduction in the expected future cash flows to be received&#13;through licensing or sale, as the Company has restructured and changed its strategy related to certain non-core assets. As a result,&#13;the Company recorded an impairment charge of $5.6 million in the third quarter of fiscal 2013, which was included in the Impairment&#13;of long-lived identified intangibles and decline in fair value of long-term investment within consolidated the statement of operations..&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The interim impairment assessment utilized Level&#13;3 inputs to estimate the fair value of the IP patents.&amp;#160;&amp;#160;We applied a discounted cash flow model based on certain scenarios,&#13;but significantly weighted towards outright sale given management&amp;#146;s intent to dispose or exclusively license the rights to&#13;these non-core IP assets.&amp;#160;&amp;#160;In estimating the fair value of these patents, we used our own assumptions about the use of&#13;the patents by a market participant and considered all available evidence. However, as our efforts to sell certain of our IP patents&#13;progresses, additional evidence may emerge that could result in an additional charge that is required to be recorded in subsequent&#13;periods.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The fair values of the GEOS and JAGTAG IP&#13;patents are presented as Intangible assets available for sale in the consolidated balance sheets, as the Company obtained&#13;approval of the board prior to November 30, 2012 to market the patents for sale, and management believes it is probable that&#13;such sale will occur within the near future, but in any event no longer than twelve months.&amp;#160;&amp;#160;We will discontinue the&#13;future amortization of the $3.5 million of patents.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;The following table presents the gross carrying&#13;value of the components of intangible assets and accumulated amortization:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="padding-bottom: 1.2pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="18" style="border-bottom: black 1.5pt solid; text-align: center; font-weight: bold"&gt;As&amp;#160;of&amp;#160;November 30, 2012&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td rowspan="3" style="padding-bottom: 1.2pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td rowspan="3" style="padding-bottom: 1.2pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" rowspan="3" style="border-bottom: black 1.5pt solid; text-align: center; font-weight: bold"&gt;Weighted Average Amortization Period (In months)&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" rowspan="3" style="padding-bottom: 1.2pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="padding-bottom: 1.2pt; text-align: center; font-weight: bold"&gt;Gross&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="padding-bottom: 1.2pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td rowspan="3" style="padding-bottom: 1.2pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" rowspan="3" style="border-bottom: black 1.5pt solid; text-align: center; font-weight: bold"&gt;Impairment Loss&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" rowspan="3" style="padding-bottom: 1.2pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td rowspan="3" style="padding-bottom: 1.2pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" rowspan="3" style="border-bottom: black 1.5pt solid; text-align: center; font-weight: bold"&gt;Transfer to Held for Sale&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" rowspan="3" style="padding-bottom: 1.2pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td rowspan="3" style="padding-bottom: 1.2pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" rowspan="3" style="border-bottom: black 1.5pt solid; text-align: center; font-weight: bold"&gt;Net&amp;#160;Carrying&amp;#160;Value&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" rowspan="3" style="padding-bottom: 1.2pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;Carrying&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;Accumulated&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; font-weight: bold"&gt;Amount&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="padding-bottom: 1.2pt; text-align: center; font-weight: bold; border-bottom: Black 2pt solid"&gt;Amortization&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left; font-style: italic; font-weight: bold; text-indent: 0.25in"&gt;Indefinite Lived Intangible:&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;Trade name&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;Indefinite&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;8,700,000&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#151;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#151;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#151;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;8,700,000&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: left; font-style: italic; font-weight: bold; text-indent: 0.25in"&gt;Definite Lived Intangibles:&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="width: 28%; text-align: left"&gt;Patent litigation&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right"&gt;84&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right"&gt;8,195,037&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right"&gt;1,709,382&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right"&gt;&amp;#151;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right"&gt;&amp;#151;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right"&gt;6,485,655&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: left"&gt;Patents&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;120&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;10,974,393&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;1,034,124&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;5,649,160&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;3,500,000&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;795,109&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;Acquired technology&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;60&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;7,270,000&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;2,102,250&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#151;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#151;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;5,167,750&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: left"&gt;Customer relationships&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;60-72&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;12,850,000&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;3,509,375&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#151;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#151;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;9,340,625&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;Software&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;36&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;2,095,706&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;2,095,706&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#151;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#151;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#151;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;Non-compete agreements&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;36&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;212,000&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;212,000&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#151;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#151;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#151;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: left"&gt;Trade names&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: right"&gt;24&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;44,000&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;44,000&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&amp;#151;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&amp;#151;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&amp;#151;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.4pt; text-align: left"&gt;Total intangibles&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;50,341,136&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;10,702,837&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;5,649,160&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;3,500,000&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;30,489,139&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="padding-bottom: 1.2pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="11" style="border-bottom: black 1.5pt solid; text-align: center; font-weight: bold"&gt;As&amp;#160;of&amp;#160;February 29, 2012&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; font-weight: bold"&gt;Weighted Average Amortization Period (In months)&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Gross&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Carrying&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Amount&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Accumulated&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Amortization&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center; font-weight: bold"&gt;Net&amp;#160;Carrying&amp;#160;Value&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left; font-style: italic; font-weight: bold"&gt;Indefinite Lived Intangible:&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&amp;#160;&amp;#160;Trade name&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;Indefinite&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;8,700,000&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#151;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;8,700,000&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: left; font-style: italic; font-weight: bold"&gt;Definite Lived Intangibles:&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="width: 52%; text-align: left"&gt;&amp;#160;&amp;#160;&amp;#160;Patent litigation&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right"&gt;84&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right"&gt;5,471,107&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right"&gt;950,150&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right"&gt;4,520,957&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&amp;#160;&amp;#160;Patents&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;120&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;6,340,300&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;292,297&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;6,048,003&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&amp;#160;&amp;#160;Acquired technology&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;60&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;7,270,000&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;1,011,750&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;6,258,250&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&amp;#160;&amp;#160;Customer relationships&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;60-72&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;12,850,000&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;1,605,625&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;11,244,375&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&amp;#160;&amp;#160;Software&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;36&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;2,095,706&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;2,095,706&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#151;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&amp;#160;&amp;#160;Non-compete agreements&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;36&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;212,000&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;185,500&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;26,500&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: left"&gt;&amp;#160;&amp;#160;&amp;#160;Trade names&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: right"&gt;24&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;44,000&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;44,000&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&amp;#151;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.4pt; text-align: left"&gt;Total intangibles&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;42,983,113&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;6,185,028&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;36,798,085&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Intangible assets relate to patent filing and&#13;patent protection litigation costs as well as customer relationships, trade names and technology obtained in past acquisitions,&#13;including the acquisitions of Hipcricket and JAGTAG during fiscal 2012. With the exception of the Hipcricket trade name carried&#13;at $8.7 million, the intangible assets have finite lives and, as such, are subject to amortization.&amp;#160;&amp;#160;Amortization of&#13;intangible assets was $1.5 million and $4.5 million for the three and nine months ended November 30, 2012.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;Amortization in future fiscal periods is expected&#13;to be as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 60%; text-align: left"&gt;Remainder of 2013&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 3%; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 35%; text-align: right"&gt;1,411,869&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;2014&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;5,247,475&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: left"&gt;2015&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;5,163,725&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;2016&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;5,014,517&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: left"&gt;2017&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;2,997,523&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: left"&gt;Thereafter&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: right"&gt;2,054,030&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.4pt; text-align: left"&gt;Total&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;21,789,139&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:LegalMattersAndContingenciesTextBlock contextRef="D2013Q2YTD">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Litigation&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In the normal course of business, we may become&#13;involved in various legal proceedings.&amp;#160;&amp;#160;Except as stated below, we know of no pending or threatened legal proceeding&#13;to which we are or will be a party that, if successful, might result in a material adverse change in our business, properties or&#13;financial condition.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Litigation Update&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Augme Technologies,&amp;#160;Inc. v. Tacoda,&amp;#160;Inc.&#13;and AOL,&amp;#160;Inc.&lt;/i&gt;&lt;/b&gt;, Civil Action No.&amp;#160;1:07-cv-07088-CM-GWG (the &amp;#147;Tacoda litigation&amp;#148;), a patent infringement&#13;lawsuit pending in the U.S. District Court for the Southern District of New York since August 2007.&amp;#160;&amp;#160;The Court ruled&#13;that the temporal scope of the Tacoda case was limited to the period before AOL began to integrate Tacoda&amp;#146;s systems into&#13;its own systems.&amp;#160;&amp;#160;Defendants represented that such integration commenced on September 28, 2007.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On August 24, 2012, Augme covenanted not to sue&#13;the defendants for any infringing activities related to the accused Tacoda systems before September 28, 2007 and thus, Augme voluntarily&#13;dismissed all claims against the defendants.&amp;#160;&amp;#160;The Stipulation of Voluntary Dismissal specifically noted that the Covenant&#13;Not To Sue would not preclude enforcement of Augme&amp;#146;s suits against AOL Inc., AOL Advertising, Inc. and Time Warner, as well&#13;as against AOL, Inc. and Gannett Co., Inc.&lt;i&gt;&amp;#160;&lt;/i&gt;The Court entered an order dismissing the case on September 4, 2012.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Augme Technologies,&amp;#160;Inc. v. AOL,&amp;#160;Inc.,&#13;AOL Advertising, Inc. and Time Warner,&amp;#160;Inc.&lt;/i&gt;&lt;/b&gt;, Civil Action No. 1:12-cv-05439-CM (transferred from Civil Action No.&amp;#160;1:09-cv-04299-RWS&#13;(S.D.N.Y.)), a patent infringement and trademark infringement lawsuit pending in the U.S. District Court for the Southern District&#13;of New York (transferred from the U.S. District Court for the Central District of California) since September&amp;#160;10, 2008.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On June 13, 2012, the patent infringement claims&#13;were transferred from Judge Robert Sweet to Judge Colleen McMahon.&amp;#160;&amp;#160;The residual claims for trademark infringement, unfair&#13;competition and false designation of origin, which remained with Judge Sweet, were dismissed by agreement of the parties on November&#13;19, 2012.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;With regards to the patent infringement claims,&#13;Time Warner filed a Motion for Judgment on the Pleadings on September 27, 2012, and, shortly thereafter, a Motion for Rule 11 Sanctions&#13;on October 23, 2012.&amp;#160;&amp;#160;On October 26, 2012, the Court &lt;i&gt;sua sponte&lt;/i&gt; stayed the case regarding any claims related to&#13;U.S. Patent No. 7,269,636, pending the outcome of the ongoing reexamination by the United States Patent and Trademark Office.&amp;#160;&amp;#160;Because&#13;the remaining patent-in-suit, U.S. Patent Nos. 6,594,691, is closely related to the &amp;#145;636 patent, Augme moved to stay the&#13;case in its entirety on November 5, 2012. All three motions are pending before the Court.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;Fact discovery is currently scheduled to&#13;be completed by the end of February 2013.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Augme Technologies,&amp;#160;Inc. v. Gannett&#13;Co.,&amp;#160;Inc., LucidMedia Networks,&amp;#160;Inc. and AOL,&amp;#160;Inc.&lt;/i&gt;&lt;/b&gt;, Civil Action No.&amp;#160;1:11-cv-05193-CM (previously &lt;i&gt;Augme&#13;Technologies,&amp;#160;Inc. v. Gannett Co.,&amp;#160;Inc., LucidMedia Networks,&amp;#160;Inc. and AOL,&amp;#160;Inc.&lt;/i&gt;, Civil Action No.&amp;#160;3:11-cv-00282-HEH&#13;(E.D.Va.)), a patent infringement lawsuit filed in the U.S. District Court for the Eastern District of Virginia on April&amp;#160;29,&#13;2011, subsequently transferred to the U.S. District Court for the Southern District of New York.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On June 24, 2011, LucidMedia Networks, Inc. filed&#13;a counterclaim against Augme in the U.S. District Court for the Eastern District of Virginia.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On April 26, 2012, Augme announced a final settlement&#13;agreement was reached with LucidMedia. LucidMedia&amp;#146;s counterclaims against Augme, pending in the Eastern District of Virginia,&#13;were dismissed pursuant to the settlement as well as Augme&amp;#146;s claims against LucidMedia pending in the Southern District of&#13;New York. The case is still pending with regards to the remaining defendants, and the parties have been engaged in the early stages&#13;of discovery. The parties&amp;#146; Opening Claim Construction briefs were submitted on June 22, 2012, and the Court issued its ruling&#13;on the disputed claim terms on August 28, 2012.&amp;#160;&amp;#160;The Court required supplemental &lt;i&gt;Markman &lt;/i&gt;briefing on one disputed&#13;claim term to be submitted by October 5, 2012.&amp;#160;&amp;#160;The parties are awaiting the Court&amp;#146;s decision on the construction&#13;of the remaining claim term, at which point discovery will resume.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Augme Technologies,&amp;#160;Inc. v. Yahoo!&#13;Inc.&lt;/i&gt;&lt;/b&gt;, Civil Action No.&amp;#160;3:09-cv-05386-JCS, a patent infringement lawsuit pending in the U.S. District Court for the&#13;Northern District of California since November&amp;#160;16, 2009.&amp;#160;&amp;#160;On December 21, 2010, Yahoo! filed a first amended answer&#13;to Augme&amp;#146;s complaint, in which Yahoo! asserted its own counterclaim against Augme alleging infringement of, &lt;i&gt;inter alia&lt;/i&gt;,&#13;U.S. Patent No. 7,640,320.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;With respect to Augme&amp;#146;s claims of patent&#13;infringement, on June 11, 2012, Yahoo! renewed its Motion for Summary Judgment of non-infringement. The Court heard argument on&#13;the summary judgment issues on July 20, 2012.&amp;#160;&amp;#160;On August 8, 2012, the Court granted Yahoo!&amp;#146;s Motion for Summary&#13;Judgment of non-infringement, dismissing Augme&amp;#146;s patent claims against Yahoo! and declining to address Augme&amp;#146;s previously&#13;filed Motion for Partial Summary Judgment of validity.&amp;#160;&amp;#160;Based on the Court&amp;#146;s summary judgment order, Augme moved&#13;for Entry of Judgment under Rule 54(b).&amp;#160;&amp;#160;Yahoo! opposed Augme&amp;#146;s motion in light of the pending counterclaim for&#13;infringement of the &amp;#145;320 patent.&amp;#160;&amp;#160;Nonetheless, Augme&amp;#146;s motion was granted by the Court on October 29, 2012,&#13;and final judgment was entered shortly thereafter on November 15, 2012.&amp;#160;&amp;#160;On December 12, 2012, Augme filed a Notice of&#13;Appeal with the district court.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;With respect to Yahoo!&amp;#146;s counterclaim regarding&#13;infringement of the &amp;#145;320 patent, the parties agreed to and filed a stipulation of infringement of this patent on December&#13;13, 2012, under the Court&amp;#146;s claim construction ruling of January 3, 2012.&amp;#160;&amp;#160;The parties also stipulated to entry&#13;of judgment under Rule 54(b) and 28 U.S.C. &amp;#167; 1292(c)(2), which permits the entry of judgment in patent cases &amp;#147;which&#13;&amp;#133; [are] final except for an accounting.&amp;#148;&amp;#160;&amp;#160;The parties also requested that the Court stay the remainder of&#13;the case pending Augme&amp;#146;s appeal to the Federal Circuit Court of Appeals.&amp;#160;&amp;#160;The Court signed such an order on December&#13;13, 2012, and entered it the next day.&amp;#160;&amp;#160;Augme&amp;#146;s Notice of Appeal to the Federal Circuit Court of Appeals regarding&#13;the stipulated infringement of Yahoo!&amp;#146;s &amp;#145;320 patent is due to be filed on Monday, January 14, 2013.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Augme Technologies,&amp;#160;Inc. v. Pandora,&amp;#160;Inc.&lt;/i&gt;&lt;/b&gt;,&#13;Civil Action No.&amp;#160;1:11-cv-00379, a patent infringement lawsuit pending in the U.S. District Court for the District of Delaware&#13;as of April&amp;#160;29, 2011. A &lt;i&gt;Markman &lt;/i&gt;hearing was held on February&amp;#160;27, 2012. The Court issued its claim construction&#13;order on December 5, 2012.&amp;#160;&amp;#160;Fact discovery has concluded, and initial expert reports are due on February 4, 2013.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Augme Technologies,&amp;#160;Inc. v. Velti,&#13;USA&lt;/i&gt;&lt;/b&gt;, Civil Action No.&amp;#160;1:12-cv-00294, a patent infringement lawsuit pending in the U.S. District Court for the District&#13;of Delaware as of March&amp;#160;9, 2012.&amp;#160;&amp;#160;Augme has filed a patent infringement lawsuit in the United States District Court&#13;of Delaware against Velti USA,&amp;#160;Inc., a global provider of mobile marketing and advertising technology and solutions. Augme&#13;is asserting three causes of action involving alleged patent infringement related to Augme-owned United States Patent No.&amp;#160;&amp;#145;721&#13;(&amp;#147;Method and Code Module for Adding Function to a Web Page&amp;#148;), United States Patent No.&amp;#160;&amp;#145;636 (&amp;#147;Method&#13;and Code Module For Adding Function to a Web Page&amp;#148;) and United States Patent No.&amp;#160;&amp;#145;691 (&amp;#147;Method and System&#13;for Adding Function to a Web Page&amp;#148;).&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On May 4, 2012, Velti filed a Motion to Dismiss&#13;For Failure to State a Claim Under Federal Rule of Civil Procedure 12(b)(6), but withdrew its Motion once Augme filed its First&#13;Amended Complaint. Velti then filed its Answer to the Amended Complaint on June 4, 2012.&amp;#160;&amp;#160;After a Rule 16 scheduling&#13;teleconference was conducted with the Court on September 19, 2012, the Court entered a Scheduling Order which set the case for&#13;a seven day jury trial beginning on June 16, 2014.&amp;#160;&amp;#160;In the meantime, the case has been referred to Magistrate Judge Sherry&#13;R. Fallon for the purpose of exploring Alternative Dispute Resolution.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Augme Technologies,&amp;#160;Inc. v. Millennial&#13;Media,&amp;#160;Inc.&lt;/i&gt;&lt;/b&gt;, Civil Action No.&amp;#160;1:12-cv-00424, a patent infringement lawsuit pending in the U.S. District Court&#13;for the District of Delaware as of April&amp;#160;5, 2012. Augme filed a case against Millennial Media,&amp;#160;Inc., asserting three&#13;causes of action involving alleged patent infringement related to Augme-owned United States Patent No.&amp;#160;7,783,721 (&amp;#147;Method&#13;and Code Module for Adding Function to a Web Page&amp;#148;), United States Patent No.&amp;#160;7,269,636 (&amp;#147;Method and Code Module&#13;For Adding Function to a Web Page&amp;#148;) and United States Patent No.&amp;#160;6,594,691 (&amp;#147;Method and System for Adding Function&#13;to a Web Page&amp;#148;).&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On May 30, 2012, Millennial Media filed a Motion&#13;to Dismiss For Failure to State a Claim Under Federal Rule of Civil Procedure 12(b)(6). Augme filed an amended complaint and an&#13;answer brief on June 18, 2012, and Millennial Media withdrew its Motion to Dismiss on June 28, 2012.&amp;#160;&amp;#160;A Scheduling Order&#13;was entered on September 28, 2012.&amp;#160;&amp;#160;The case has been set for a seven day jury trial beginning on September 15, 2014.&amp;#160;&amp;#160;In&#13;the meantime, the case has been referred to Magistrate Judge Sherry R. Fallon for the purpose of exploring Alternative Dispute&#13;Resolution.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;The Reexamination of the &amp;#145;636 Patent.&amp;#160;&amp;#160;&lt;/i&gt;&lt;/b&gt;In&#13;connection with Yahoo!&amp;#146;s defense of Augme&amp;#146;s claims in the counterclaim asserted in Augme Technologies,&amp;#160;Inc. v.&#13;Yahoo! Inc., on August 31, 2011, Yahoo! filed a Request for Inter Partes Reexamination of Augme&amp;#146;s U.S. Patent No. 7,269,636&#13;(Reexamination Control No. 95/001,734).&amp;#160; The United States Patent and Trademark Office granted Yahoo!&amp;#146;s request in a&#13;Reexamination Grant Order mailed on November 30, 2011. On August 14, 2012, the Examiner responsible for this reexamination proceeding&#13;issued a non-final Action Closing Prosecution, in which he rejected claims 1-4, 9, 14, 20, 21 and 25.&amp;#160; The other claims of&#13;the &amp;#145;636 patent are not subject to reexamination.&amp;#160; On September 14, 2012, Augme filed a Response to the Action Closing&#13;Prosecution, responding to the grounds for rejection presented by the Examiner.&amp;#160; On October 15, 2012, Yahoo! submitted its&#13;comments to Augme&amp;#146;s September 14 Response to the Action Closing Prosecution.&amp;#160; Currently, this matter remains pending.&lt;font style="font-size: 8pt"&gt;&amp;#160;&#13;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;The Reexamination of the &amp;#145;320 Patent.&#13;&lt;/i&gt;&lt;/b&gt;In connection with Augme&amp;#146;s defense against Yahoo!&amp;#146;s counterclaim in Augme Technologies,&amp;#160;Inc. v. Yahoo!&#13;Inc., on October 26, 2011, Augme filed a Request for Inter Partes Reexamination of Yahoo!&amp;#146;s U.S. Patent No. 7,640,320 (Reexamination&#13;Control No. 95/001,794).&amp;#160; The United States Patent and Trademark Office issued an Order Granting Augme&amp;#146;s Request for&#13;Inter Partes Reexamination on December 20, 2011. On the same day, the Examiner issued an Office Action rejecting claims 1-4 and&#13;6-10 of the &amp;#145;320 patent.&amp;#160; On February 21, 2012, Yahoo! filed a Response to the December 20 Office Action, and on March&#13;22, 2012, Augme submitted its comments in light of the December 20 Office Action and Yahoo!&amp;#146;s February 21 Response.&amp;#160;&#13;Shortly thereafter, on April 19, 2012, the Examiner issued an Action Closing Prosecution confirming claims 3 and 9, and rejecting&#13;claims 1,2,4, 6-8 and 10.&amp;#160; Yahoo! filed comments in response on May 21, 2012, and Augme did the same on June 20, 2012. The&#13;Examiner then issued a Right of Appeal Notice (&amp;#147;RAN&amp;#148;) on July 31, 2012, withdrawing the previous rejections and confirming&#13;claims 1-4 and 6-10.&amp;#160; Augme appealed this decision to the Board of Appeals on August 31, 2012 and filed its brief on October&#13;31, 2012.&amp;#160; Yahoo! filed its rebuttal brief on November 30, 2012. Currently, this matter remains pending.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Brandofino Communications vs. Augme Technologies,&amp;#160;Inc.&#13;&lt;/i&gt;&lt;/b&gt;On September&amp;#160;27, 2011 Brandofino Communications,&amp;#160;Inc. (&amp;#147;Brandofino&amp;#148;) filed suit against Augme and&#13;New Aug LLC in the Supreme Court of the State of New York, New York County. The complaint alleges, &lt;i&gt;inter alia&lt;/i&gt;, breach of&#13;contract and unjust enrichment claims arising from work Brandofino allegedly performed for Augme pursuant to a marketing agreement&#13;entered into by Brandofino and Augme. Augme has served its Answer and set forth counterclaims for breach of contract, unfair competition,&#13;tortious interference with business relations, and violations of New York General Business Law Section&amp;#160;349 (relating to violations&#13;of Augme&amp;#146;s intellectual property rights). The Company intends to vigorously defend against Brandofino&amp;#146;s claim and pursue&#13;its counterclaims.&lt;/p&gt;</us-gaap:LegalMattersAndContingenciesTextBlock>
    <us-gaap:ConcentrationRiskDisclosureTextBlock contextRef="D2013Q2YTD">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the quarter ended November 30, 2012, three&#13;customers accounted for approximately 9.0 percent, 6.2 percent&amp;#160;and 5.3 percent of the Company&amp;#146;s revenue and no other&#13;customer accounted for over 5 percent of revenues.&amp;#160;&amp;#160;During the quarter ended November 30, 2011 there were three customers&#13;that accounted for approximately 23 percent of revenues.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the nine months ended November 30, 2012,&#13;two customers accounted for approximately 9.9 percent and 7.4 percent of the Company&amp;#146;s revenue and no other customer accounted&#13;for over 5 percent of revenues.&amp;#160;&amp;#160;During the nine months ended November 30, 2011 there were three customers that accounted&#13;for approximately 23 percent of revenues.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;At November 30, 2012, three customers accounted&#13;for 29 percent of accounts receivable, the largest of which accounted for 11.7 percent.&amp;#160; At February&amp;#160;29, 2012, three&#13;customers accounted for 25 percent of accounts receivable, the largest of which accounted for 10.8 percent.&lt;/p&gt;</us-gaap:ConcentrationRiskDisclosureTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="I2012" unitRef="USD" decimals="0">36798085</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="I2013Q2" unitRef="USD" decimals="0">21789139</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2012-11-30_TradeNamesMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2012-11-30_NoncompeteAgreementsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2012-11-30_SoftwareMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2012-11-30_CustomerRelationshipsMember" unitRef="USD" decimals="0">9340625</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2012-11-30_AcquiredTechnologyMember" unitRef="USD" decimals="0">5167750</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2012-11-30_PatentsMember" unitRef="USD" decimals="0">795109</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2012-11-30_PatentLitigationMember" unitRef="USD" decimals="0">6485655</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="I2012_TradeNamesMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="I2012_NoncompeteAgreementsMember" unitRef="USD" decimals="0">26500</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="I2012_SoftwareMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="I2012_CustomerRelationshipsMember" unitRef="USD" decimals="0">11244375</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="I2012_AcquiredTechnologyMember" unitRef="USD" decimals="0">6258250</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="I2012_PatentsMember" unitRef="USD" decimals="0">6048003</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="I2012_PatentLitigationMember" unitRef="USD" decimals="0">4520957</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2012-02-29_TradeNameMember" unitRef="USD" decimals="0">8700000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2012-11-30_TradeNameMember" unitRef="USD" decimals="0">8700000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="I2012" unitRef="USD" decimals="0">6185028</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="I2013Q2" unitRef="USD" decimals="0">10702837</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2012-11-30_TradeNamesMember" unitRef="USD" decimals="0">44000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2012-11-30_NoncompeteAgreementsMember" unitRef="USD" decimals="0">212000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2012-11-30_SoftwareMember" unitRef="USD" decimals="0">2095706</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2012-11-30_CustomerRelationshipsMember" unitRef="USD" decimals="0">3509375</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2012-11-30_AcquiredTechnologyMember" unitRef="USD" decimals="0">2102250</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2012-11-30_PatentsMember" unitRef="USD" decimals="0">1034124</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2012-11-30_PatentLitigationMember" unitRef="USD" decimals="0">1709382</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="I2012_TradeNamesMember" unitRef="USD" decimals="0">44000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="I2012_NoncompeteAgreementsMember" unitRef="USD" decimals="0">185500</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="I2012_SoftwareMember" unitRef="USD" decimals="0">2095706</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="I2012_CustomerRelationshipsMember" unitRef="USD" decimals="0">1605625</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="I2012_AcquiredTechnologyMember" unitRef="USD" decimals="0">1011750</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="I2012_PatentsMember" unitRef="USD" decimals="0">292297</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="I2012_PatentLitigationMember" unitRef="USD" decimals="0">950150</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2012-02-29_TradeNameMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2012-11-30_TradeNameMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="I2012" unitRef="USD" decimals="0">42983113</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="I2013Q2" unitRef="USD" decimals="0">50341136</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2012-11-30_TradeNamesMember" unitRef="USD" decimals="0">44000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2012-11-30_NoncompeteAgreementsMember" unitRef="USD" decimals="0">212000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2012-11-30_SoftwareMember" unitRef="USD" decimals="0">2095706</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2012-11-30_CustomerRelationshipsMember" unitRef="USD" decimals="0">12850000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2012-11-30_AcquiredTechnologyMember" unitRef="USD" decimals="0">7270000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2012-11-30_PatentsMember" unitRef="USD" decimals="0">10974393</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2012-11-30_PatentLitigationMember" unitRef="USD" decimals="0">8195037</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="I2012_TradeNamesMember" unitRef="USD" decimals="0">44000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="I2012_NoncompeteAgreementsMember" unitRef="USD" decimals="0">212000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="I2012_SoftwareMember" unitRef="USD" decimals="0">2095706</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="I2012_CustomerRelationshipsMember" unitRef="USD" decimals="0">12850000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="I2012_AcquiredTechnologyMember" unitRef="USD" decimals="0">7270000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="I2012_PatentsMember" unitRef="USD" decimals="0">6340300</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="I2012_PatentLitigationMember" unitRef="USD" decimals="0">5471107</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2012-02-29_TradeNameMember" unitRef="USD" decimals="0">8700000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2012-11-30_TradeNameMember" unitRef="USD" decimals="0">8700000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="From2012-03-01to2012-11-30_CustomerRelationshipsMember_MaximumMember">P72M</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="From2012-03-01to2012-11-30_TradeNamesMember">P24M</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="From2012-03-01to2012-11-30_NoncompeteAgreementsMember">P36M</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="From2012-03-01to2012-11-30_SoftwareMember">P36M</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="From2012-03-01to2012-11-30_CustomerRelationshipsMember_MinimumMember">P60M</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="From2012-03-01to2012-11-30_AcquiredTechnologyMember">P60M</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="From2012-03-01to2012-11-30_PatentsMember">P120M</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="From2012-03-01to2012-11-30_PatentLitigationMember">P84M</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="D2012_TradeNamesMember">P24M</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="D2012_NoncompeteAgreementsMember">P36M</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="D2012_SoftwareMember">P36M</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="D2012_CustomerRelationshipsMember_MaximumMember">P72M</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="D2012_CustomerRelationshipsMember_MinimumMember">P60M</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="D2012_AcquiredTechnologyMember">P60M</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="D2012_PatentsMember">P120M</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="D2012_PatentLitigationMember">P84M</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <augt:ImpairmentOfIntangibleAssets contextRef="I2013Q2" unitRef="USD" decimals="0">5649160</augt:ImpairmentOfIntangibleAssets>
    <augt:ImpairmentOfIntangibleAssets contextRef="AsOf2012-11-30_TradeNamesMember" unitRef="USD" xsi:nil="true" />
    <augt:ImpairmentOfIntangibleAssets contextRef="AsOf2012-11-30_NoncompeteAgreementsMember" unitRef="USD" xsi:nil="true" />
    <augt:ImpairmentOfIntangibleAssets contextRef="AsOf2012-11-30_SoftwareMember" unitRef="USD" xsi:nil="true" />
    <augt:ImpairmentOfIntangibleAssets contextRef="AsOf2012-11-30_CustomerRelationshipsMember" unitRef="USD" xsi:nil="true" />
    <augt:ImpairmentOfIntangibleAssets contextRef="AsOf2012-11-30_AcquiredTechnologyMember" unitRef="USD" xsi:nil="true" />
    <augt:ImpairmentOfIntangibleAssets contextRef="AsOf2012-11-30_PatentsMember" unitRef="USD" decimals="0">5649160</augt:ImpairmentOfIntangibleAssets>
    <augt:ImpairmentOfIntangibleAssets contextRef="AsOf2012-11-30_PatentLitigationMember" unitRef="USD" xsi:nil="true" />
    <augt:ImpairmentOfIntangibleAssets contextRef="AsOf2012-11-30_TradeNameMember" unitRef="USD" xsi:nil="true" />
    <augt:IntangibleAssetsTransferToHeldForSale contextRef="I2013Q2" unitRef="USD" decimals="0">3500000</augt:IntangibleAssetsTransferToHeldForSale>
    <augt:IntangibleAssetsTransferToHeldForSale contextRef="AsOf2012-11-30_TradeNamesMember" unitRef="USD" xsi:nil="true" />
    <augt:IntangibleAssetsTransferToHeldForSale contextRef="AsOf2012-11-30_NoncompeteAgreementsMember" unitRef="USD" xsi:nil="true" />
    <augt:IntangibleAssetsTransferToHeldForSale contextRef="AsOf2012-11-30_SoftwareMember" unitRef="USD" xsi:nil="true" />
    <augt:IntangibleAssetsTransferToHeldForSale contextRef="AsOf2012-11-30_CustomerRelationshipsMember" unitRef="USD" xsi:nil="true" />
    <augt:IntangibleAssetsTransferToHeldForSale contextRef="AsOf2012-11-30_AcquiredTechnologyMember" unitRef="USD" xsi:nil="true" />
    <augt:IntangibleAssetsTransferToHeldForSale contextRef="AsOf2012-11-30_PatentsMember" unitRef="USD" decimals="0">3500000</augt:IntangibleAssetsTransferToHeldForSale>
    <augt:IntangibleAssetsTransferToHeldForSale contextRef="AsOf2012-11-30_PatentLitigationMember" unitRef="USD" xsi:nil="true" />
    <augt:IntangibleAssetsTransferToHeldForSale contextRef="AsOf2012-11-30_TradeNameMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear contextRef="I2013Q2" unitRef="USD" decimals="0">1411869</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="I2013Q2" unitRef="USD" decimals="0">5247475</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="I2013Q2" unitRef="USD" decimals="0">5163725</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="I2013Q2" unitRef="USD" decimals="0">5014517</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive contextRef="I2013Q2" unitRef="USD" decimals="0">2997523</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive contextRef="I2013Q2" unitRef="USD" decimals="0">2054030</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived contextRef="From2012-09-01to2012-11-30" unitRef="USD" decimals="INF">9300000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived contextRef="D2013Q2YTD" unitRef="USD" decimals="INF">5600000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <augt:FutureAmortizationOfPatents contextRef="D2013Q2YTD" unitRef="USD" decimals="INF">3500000</augt:FutureAmortizationOfPatents>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="From2012-09-01to2012-11-30" unitRef="USD" decimals="INF">1500000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="D2013Q2YTD" unitRef="USD" decimals="INF">4500000</us-gaap:AmortizationOfIntangibleAssets>
    <augt:HipcricketTradeNameCarriedAmount contextRef="From2012-03-01to2013-02-28" unitRef="USD" decimals="INF">8700000</augt:HipcricketTradeNameCarriedAmount>
    <us-gaap:EntityWideRevenueMajorCustomerPercentage contextRef="From2012-09-01to2012-11-30_CustomerOneMember" unitRef="Pure" decimals="INF">0.09</us-gaap:EntityWideRevenueMajorCustomerPercentage>
    <us-gaap:EntityWideRevenueMajorCustomerPercentage contextRef="From2012-03-01to2012-11-30_CustomerOneMember" unitRef="Pure" decimals="INF">0.099</us-gaap:EntityWideRevenueMajorCustomerPercentage>
    <us-gaap:EntityWideRevenueMajorCustomerPercentage contextRef="From2012-09-01to2012-11-30_CustomerTwoMember" unitRef="Pure" decimals="INF">0.062</us-gaap:EntityWideRevenueMajorCustomerPercentage>
    <us-gaap:EntityWideRevenueMajorCustomerPercentage contextRef="From2012-03-01to2012-11-30_CustomerTwoMember" unitRef="Pure" decimals="INF">0.074</us-gaap:EntityWideRevenueMajorCustomerPercentage>
    <us-gaap:EntityWideRevenueMajorCustomerPercentage contextRef="From2012-09-01to2012-11-30_CustomerThreeMember" unitRef="Pure" decimals="INF">0.053</us-gaap:EntityWideRevenueMajorCustomerPercentage>
    <us-gaap:EntityWideRevenueMajorCustomerPercentage contextRef="From2011-09-01to2011-11-30_ThreeCustomersMember" unitRef="Pure" decimals="INF">0.23</us-gaap:EntityWideRevenueMajorCustomerPercentage>
    <us-gaap:EntityWideRevenueMajorCustomerPercentage contextRef="From2011-03-01to2011-11-30_ThreeCustomersMember" unitRef="Pure" decimals="INF">0.23</us-gaap:EntityWideRevenueMajorCustomerPercentage>
    <us-gaap:EntityWideRevenueMajorCustomerPercentage contextRef="From2012-03-01to2012-11-30_NoOtherCustomers" unitRef="Pure" decimals="INF">0.05</us-gaap:EntityWideRevenueMajorCustomerPercentage>
    <us-gaap:EntityWideRevenueMajorCustomerPercentage contextRef="From2012-09-01to2012-11-30_NoOtherCustomers" unitRef="Pure" decimals="INF">0.05</us-gaap:EntityWideRevenueMajorCustomerPercentage>
    <augt:EntityWideAccountsReceivablesMajorCustomerPercentage contextRef="AsOf2012-11-30_MinimumMember" unitRef="Pure" decimals="INF">0.117</augt:EntityWideAccountsReceivablesMajorCustomerPercentage>
    <augt:EntityWideAccountsReceivablesMajorCustomerPercentage contextRef="AsOf2012-02-29_MinimumMember" unitRef="Pure" decimals="INF">0.108</augt:EntityWideAccountsReceivablesMajorCustomerPercentage>
    <augt:EntityWideAccountsReceivablesMajorCustomerPercentage contextRef="AsOf2012-11-30_MaximumMember" unitRef="Pure" decimals="INF">0.29</augt:EntityWideAccountsReceivablesMajorCustomerPercentage>
    <augt:EntityWideAccountsReceivablesMajorCustomerPercentage contextRef="AsOf2012-02-29_MaximumMember" unitRef="Pure" decimals="INF">0.25</augt:EntityWideAccountsReceivablesMajorCustomerPercentage>
    <us-gaap:LiquidityDisclosureTextBlock contextRef="D2013Q2YTD">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction&#13;of liabilities in the normal course of business. As of November 30, 2012 and February 29, 2012, the Company had accumulated deficits&#13;of $87.4 million and $72.5 million, respectively. The Company is subject to the risks and challenges associated with companies&#13;at a similar stage of development including dependence on key individuals, challenges related to the successful development and&#13;marketing of its products and services, the integration of business combinations, and competition from substitute products and&#13;services and larger companies with greater financial, technical management and marketing resources. As of November 30, 2012, the&#13;Company had working capital of $2.9 million, and cash and cash equivalents of $1.8 million. In order to fund existing operations&#13;for the remainder of fiscal 2013 and into fiscal 2014, the Company will need to raise additional cash through equity or debt financings,&#13;and/or sell certain strategic assets, such as its purchased technology or patent portfolio.&amp;#160;&amp;#160;There is no certainty that&#13;the Company has the ability to raise additional funds through debt or equity financings under terms acceptable to the Company,&#13;or that the Company has the ability to sell strategic assets, which, if a sale is completed, may adversely affect ongoing operations.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;Company operates in the mobile marketing industry and accordingly, can be affected by a variety of factors. For example, management&#13;of the Company believes that any of the following factors could have a significant negative effect on the Company&amp;#146;s future&#13;financial position, results of operations and cash flows: lack of cash and the ability to raise cash as and when needed; unanticipated&#13;fluctuations in quarterly operating results, adverse changes in the Company&amp;#146;s relationship with significant customers or&#13;failure to secure contracts with other customers, intense competition, failure to attract and retain key personnel, failure to&#13;protect intellectual property, decrease in the migration trends from traditional advertising methods to digital and mobile media&#13;and the inability to manage growth.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;September 2012, the Company adopted a restructuring plan which includes reducing the number of employees, slowing the pace of&#13;investments in our IP portfolio and minimizing variable expenses. The Company is restructuring overall corporate overhead expenses&#13;in order to focus our business around our mobile marketing and advertising technology and services. We intend to minimize cash&#13;spend while carefully investing our resources and protecting our strategic assets to strengthen our position in the mobile marketing&#13;and mobile advertising industry. We believe that the restructuring plan will improve cash flow by approximately $6.0 million on&#13;an annual basis.&amp;#160;&amp;#160;Cash used to pay for costs associated with one-time contract termination and termination benefits&#13;during the third quarter ended November 30, 2012 was $0.4 million. We expect to use additional cash of $0.4 million during the&#13;fourth quarter of fiscal 2013 for restructuring.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;September 2012, we borrowed a total of $450,000 from two lenders. The loans were used for working capital. We borrowed&amp;#160;&amp;#160;$250,000&#13;from one lender.&amp;#160;&amp;#160;This loan bears interest at the rate of 12% per year and is due to be paid on the earlier of the first&#13;anniversary of the loan, the closing of a financing transaction through which we raise gross proceeds of not less than $10 million,&#13;an event of default as defined in the promissory note or upon a change of control as defined in the promissory note. In addition,&#13;we issued a note payable in the amount of $200,000 to Ernest W. Purcell, a former director. This loan was paid in full in October&#13;2012.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;On October 3, 2012, we completed a public offering&#13;of our securities pursuant to which we sold 8.5 million shares of common stock registered on a Form S-3 registration statement&#13;at a price to the public of $0.80 per share. We also issued warrants to purchase an additional 2.125 million shares of common&#13;stock at an exercise price of $0.96 per share. We raised $6.2 million in proceeds, net of $0.6 million in costs related to the&#13;offering, leaving approximately $48.0 million of the $75.0 million registered on the Form S-3 registration statement, which we&#13;filed in June 2011. We intend to use the net proceeds from this offering for organic expansion in existing and new markets and&#13;for general corporate purposes.&lt;/font&gt;&lt;/p&gt;</us-gaap:LiquidityDisclosureTextBlock>
    <us-gaap:UseOfEstimates contextRef="D2013Q2YTD">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The preparation of financial statements in&#13;conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that&#13;affect the amounts reported in the financial statements. We regularly evaluate estimates and judgments based on historical experience&#13;and other relevant facts and circumstances. Actual results could differ from those estimates. Significant estimates relate to fair&#13;value of assets acquired and liabilities assumed in business combinations, acquisition related contingent consideration, allowances&#13;for tax assets, the use of the Black-Scholes pricing model for valuing stock option and common stock warrant issuances, estimates&#13;of future cash flows used to evaluate impairment of long-lived assets, revenues earned from percentage of completion contracts&#13;and the period in which revenues should be recorded.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription contextRef="D2013Q2YTD">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Certain reclassifications have been made to&#13;prior periods to conform to current reporting. The presentation of our Consolidated Statements of Operations has been adjusted&#13;for the reclassification of operating expenses to be presented in the following categories: sales and marketing, technology and&#13;development, general and administrative and depreciation and amortization.&amp;#160;&amp;#160;The operating expenses for the three and&#13;nine months ended November 30, 2011 have been reclassified accordingly.&lt;/p&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="D2013Q2YTD">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The condensed consolidated financial statements&#13;have been prepared in accordance with accounting principles generally accepted in the United States of America and pursuant to&#13;the rules and regulations of the SEC. The same accounting policies are followed for preparing the quarterly and annual financial&#13;information unless otherwise disclosed in the notes below.&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="D2013Q2YTD">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In July 2012, the FASB issued ASU&amp;#160;2012-02,&#13;&amp;#147;Testing Indefinite-Lived Intangible Assets for Impairment.&amp;#148; ASU 2012-02 amends the guidance in ASC 350-30 on testing&#13;indefinite-lived intangible assets, other than goodwill, for impairment.&amp;#160;&amp;#160;Under ASU 2012-02, an entity has the option&#13;of performing a qualitative assessment of whether it is more likely than not that the fair value of an entity&amp;#146;s indefinite-lived&#13;intangible asset is less than its carrying amount before calculating the fair value of the asset. If the conclusion is that it&#13;is more likely than not that the fair value of an indefinite-lived intangible asset is less than its carrying amount, the company&#13;would be required to calculate the fair value of the asset. ASU 2012-02 is effective for annual and interim impairment tests performed&#13;for fiscal years beginning after September&amp;#160;15, 2012, with early adoption permitted. We early adopted this guidance as of August&#13;31, 2012 in connection with our interim impairment assessment and it did not have a material impact on our financial position,&#13;results of operations, or cash flows.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="D2013Q2YTD">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The estimated fair values of our stock option&#13;awards were determined using the following weighted average assumptions:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: justify; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; padding-bottom: 1.2pt"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Three&amp;#160;Months&amp;#160;Ended&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;November 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: justify; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: justify; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Nine&amp;#160;Months&amp;#160;Ended&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;November 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: justify; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: justify; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; padding-bottom: 1.2pt; text-align: justify; font-weight: bold"&gt;2012&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: justify; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: justify; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; padding-bottom: 1.2pt; text-align: justify; font-weight: bold"&gt;2011&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: justify; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: justify; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; padding-bottom: 1.2pt; text-align: justify; font-weight: bold"&gt;2012&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: justify; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: justify; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: justify; font-weight: bold"&gt;2011&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: justify; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 52%; text-align: justify"&gt;Expected dividends&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: justify"&gt;0&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; text-align: justify"&gt;%&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: justify"&gt;0&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; text-align: justify"&gt;%&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: justify"&gt;0&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; text-align: justify"&gt;%&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: justify"&gt;0&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; text-align: justify"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify"&gt;Expected term (in years)&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;3.50&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;5&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;3.50&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;5&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: justify"&gt;Weighted-average volatility&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;65.00&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;%&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;77.70&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;%&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;62.38&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;%&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;77.70&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify"&gt;Risk-free rate&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;0.43&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;%&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;0.40&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;%&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;0.44&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;%&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;0.40&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="D2013Q2YTD">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The effect on our results of operations of&#13;recording share-based compensation expense for the three and nine months ended November 30, 2012 and 2011 was as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: justify; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; padding-bottom: 1.2pt"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Three&amp;#160;Months&amp;#160;Ended&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;November 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: justify; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: justify; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Nine&amp;#160;Months&amp;#160;Ended&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;November 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: justify; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: justify; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; padding-bottom: 1.2pt; text-align: justify; font-weight: bold"&gt;2012&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: justify; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: justify; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; padding-bottom: 1.2pt; text-align: justify; font-weight: bold"&gt;2011&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: justify; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: justify; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; padding-bottom: 1.2pt; text-align: justify; font-weight: bold"&gt;2012&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: justify; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: justify; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: justify; font-weight: bold"&gt;2011&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: justify; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 52%; text-align: justify"&gt;Selling and marketing&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: justify"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: justify"&gt;379,756&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: justify"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: justify"&gt;1,043,590&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: justify"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: justify"&gt;1,407,393&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: justify"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: justify"&gt;2,104,527&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify"&gt;Technology and development&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;272,621&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;425,449&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;882,591&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;857,970&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: justify"&gt;General and administrative&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; padding-bottom: 1.2pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; padding-bottom: 1.2pt; text-align: justify"&gt;534,876&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; padding-bottom: 1.2pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; padding-bottom: 1.2pt; text-align: justify"&gt;846,961&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; padding-bottom: 1.2pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; padding-bottom: 1.2pt; text-align: justify"&gt;1,389,460&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: justify"&gt;1,708,001&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 2.4pt; text-align: justify"&gt;Total stock-based compensation expense&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.4pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; padding-bottom: 2.4pt; text-align: justify"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; padding-bottom: 2.4pt; text-align: justify"&gt;1,187,253&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.4pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.4pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; padding-bottom: 2.4pt; text-align: justify"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; padding-bottom: 2.4pt; text-align: justify"&gt;2,316,000&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.4pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.4pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; padding-bottom: 2.4pt; text-align: justify"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; padding-bottom: 2.4pt; text-align: justify"&gt;3,679,444&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.4pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.4pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: justify"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: justify"&gt;4,670,498&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.4pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="D2013Q2YTD">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The summary of activity for Augme&amp;#146;s stock&#13;options is presented below:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: justify; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; padding-bottom: 1.2pt"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Number&amp;#160;of&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: justify; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: justify; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; padding-bottom: 1.2pt"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Exercise&amp;#160;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: justify; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: justify; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Average Remaining Contractual Term&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;(In Years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: justify; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 56%; text-align: justify"&gt;Options outstanding at February&amp;#160;29, 2012&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: justify"&gt;20,153,219&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: justify"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: justify"&gt;2.13&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 15%; text-align: justify"&gt;3.81&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify"&gt;Granted&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;2,850,268&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;1.48&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: justify"&gt;Exercised&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;(572,092&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;)&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;0.53&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: justify"&gt;Forfeited, cancelled and expired&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; padding-bottom: 1.2pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; padding-bottom: 1.2pt; text-align: justify"&gt;(3,964,603&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: justify"&gt;)&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: justify"&gt;2.41&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: justify"&gt;Options outstanding at November 30, 2012&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;18,466,792&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;2.04&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;3.22&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: justify"&gt;Options vested and expected to vest at November 30, 2012&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;17,570,483&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;2.03&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;3.18&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify"&gt;Options exercisable at November 30, 2012&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;12,491,061&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;1.96&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;2.84&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <augt:ScheduleOfShareBasedPaymentAwardStockWarrantAwardsValuationAssumptionsTableTextBlock contextRef="D2013Q2YTD">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The estimated fair values of our stock warrant&#13;awards issued to service providers and employees were determined using the following weighted average assumptions:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: justify; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; padding-bottom: 1.2pt"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Three&amp;#160;Months&amp;#160;Ended&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;November 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: justify; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: justify; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Nine&amp;#160;Months&amp;#160;Ended&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;November 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: justify; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: justify; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; padding-bottom: 1.2pt; text-align: justify; font-weight: bold"&gt;2012&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: justify; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: justify; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; padding-bottom: 1.2pt; text-align: justify; font-weight: bold"&gt;2011&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: justify; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: justify; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; padding-bottom: 1.2pt; text-align: justify; font-weight: bold"&gt;2012&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: justify; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: justify; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: justify; font-weight: bold"&gt;2011&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: justify; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 52%; text-align: justify"&gt;Expected dividends&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: justify"&gt;0&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; text-align: justify"&gt;%&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: justify"&gt;0&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; text-align: justify"&gt;%&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: justify"&gt;0&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; text-align: justify"&gt;%&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: justify"&gt;0&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; text-align: justify"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify"&gt;Term (in years)&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;5.00&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;3&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;4.75&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;3. 9&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: justify"&gt;Weighted-average volatility&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;65.00&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;%&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;81.32&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;%&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;64.37&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;%&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;77.80&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify"&gt;Risk-free rate&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;0.62&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;%&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;0.40&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;%&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;0.59&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;%&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;0.40&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</augt:ScheduleOfShareBasedPaymentAwardStockWarrantAwardsValuationAssumptionsTableTextBlock>
    <augt:ScheduleOfEmployeeAndNonemployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="D2013Q2YTD">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The warrant expense for the three and nine&#13;months ended November 30, 2012 and 2011 is as follows, and is included in general and administrative expense:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: justify; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; padding-bottom: 1.2pt"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Three&amp;#160;Months&amp;#160;Ended&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;November 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: justify; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: justify; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Nine&amp;#160;Months&amp;#160;Ended&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;November 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: justify; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: justify; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; padding-bottom: 1.2pt; text-align: justify; font-weight: bold"&gt;2012&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: justify; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: justify; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; padding-bottom: 1.2pt; text-align: justify; font-weight: bold"&gt;2011&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: justify; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: justify; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; padding-bottom: 1.2pt; text-align: justify; font-weight: bold"&gt;2012&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: justify; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: justify; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: justify; font-weight: bold"&gt;2011&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: justify; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 52%; padding-bottom: 2.4pt; text-align: justify"&gt;Total warrant expense&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 2.4pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 2.25pt double; padding-bottom: 2.4pt; text-align: justify"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 9%; border-bottom: black 2.25pt double; padding-bottom: 2.4pt; text-align: justify"&gt;188,849&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 2.4pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 2.4pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 2.25pt double; padding-bottom: 2.4pt; text-align: justify"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 9%; border-bottom: black 2.25pt double; padding-bottom: 2.4pt; text-align: justify"&gt;1,193,943&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 2.4pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 2.4pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 2.25pt double; padding-bottom: 2.4pt; text-align: justify"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 9%; border-bottom: black 2.25pt double; padding-bottom: 2.4pt; text-align: justify"&gt;622,915&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 2.4pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 2.4pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 2.25pt double; text-align: justify"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 9%; border-bottom: black 2.25pt double; text-align: justify"&gt;2,339,790&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 2.4pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</augt:ScheduleOfEmployeeAndNonemployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="D2013Q2YTD">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The summary of activity for Augme&amp;#146;s warrants&#13;is presented below:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: justify; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; padding-bottom: 1.2pt; text-align: justify; font-weight: bold"&gt;Number&amp;#160;of&amp;#160;Warrants&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: justify; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1.5pt solid; padding-bottom: 1.2pt"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Exercise&amp;#160;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: justify; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: justify; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: justify; font-weight: bold"&gt;Average Remaining Contractual Term (In Years)&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: justify; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 56%; text-align: justify"&gt;Warrants outstanding at February&amp;#160;29, 2012&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: justify"&gt;10,787,641&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: justify"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: justify"&gt;1.86&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 15%; text-align: justify"&gt;2.99&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify"&gt;Granted&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;3,187,499&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;1.17&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: justify"&gt;Exercised&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;(1,000,000&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;)&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;1.00&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: justify"&gt;Forfeited, cancelled and expired&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: justify; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; padding-bottom: 1.2pt; text-align: justify; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; padding-bottom: 1.2pt; text-align: justify; font-weight: bold"&gt;&amp;#151;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: justify; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: justify; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: justify; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: justify; font-weight: bold"&gt;&amp;#151;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: justify; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: justify"&gt;Warrants outstanding at November 30, 2012&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;12,975,140&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;1.76&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;2.77&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: justify"&gt;Warrants vested and expected to vest at November 30, 2012&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;12,932,640&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;1.76&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;2.76&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify"&gt;Warrants exercisable and outstanding at November 30, 2012&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;12,312,642&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;1.76&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;2.69&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="D2013Q2YTD">&lt;p style="margin: 0pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following table presents the change in&#13;Level&amp;#160;3 acquisition related contingent consideration liability measured on a recurring basis for the three months ended November&#13;30, 2012:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;August 31,&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1.5pt solid; text-align: justify; font-weight: bold"&gt;Cash and Stock Payments&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1.5pt solid"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;(Gain)&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&amp;#160;Included in&amp;#160;Earnings&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1.5pt solid; text-align: justify; font-weight: bold"&gt;November 30, 2012&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: justify"&gt;Acquisition related contingent consideration&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;10,999,890&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;(3,621,056)&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;(7,339,173)&lt;/td&gt;&#13;    &lt;td style="text-align: justify; font-size: 7pt"&gt;(1)&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;39,661&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 3%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 87%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 8%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following table presents the change in&#13;Level&amp;#160;3 acquisition related contingent consideration liability measured on a recurring basis for the nine months ended November&#13;30, 2012:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;February 29,&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1.5pt solid; text-align: justify; font-weight: bold"&gt;Cash and Stock Payments&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1.5pt solid"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;(Gain)&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&amp;#160;Included in&amp;#160;Earnings&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1.5pt solid; text-align: justify; font-weight: bold"&gt;November 30, 2012&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 46%; text-align: justify"&gt;Acquisition related contingent consideration&lt;/td&gt;&#13;    &lt;td style="width: 4%; text-align: justify"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: justify"&gt;26,000,500&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 3%; text-align: justify"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: justify"&gt;(13,761,109)&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%; text-align: justify"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: justify"&gt;(12,199,730)&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: justify; font-size: 7pt"&gt;(1)&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 6%; text-align: justify"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 5%; text-align: justify"&gt;39,661&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:BusinessAcquisitionProFormaInformationTextBlock contextRef="D2013Q2YTD">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The pro-forma results of operations for the&#13;nine months ended November 30, 2011 are as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: justify; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: justify; font-weight: bold"&gt;Nine Months Ended November 30, 2011&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: justify; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 82%; text-align: justify"&gt;Revenues&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: justify"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 15%; text-align: justify"&gt;11,851,321&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify"&gt;Net loss&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;(21,985,225&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: justify"&gt;Weighted average common shares&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;82,905,010&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify"&gt;Basic and diluted net loss per share&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;(0.27&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:BusinessAcquisitionProFormaInformationTextBlock>
    <augt:ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTableTextBlock contextRef="D2013Q2YTD">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following table presents the gross carrying&#13;value of the components of intangible assets and accumulated amortization:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="padding-bottom: 1.2pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: justify; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="18" style="border-bottom: black 1.5pt solid; text-align: justify; font-weight: bold"&gt;As&amp;#160;of&amp;#160;November 30, 2012&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: justify; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td rowspan="3" style="padding-bottom: 1.2pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td rowspan="3" style="padding-bottom: 1.2pt; text-align: justify; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" rowspan="3" style="border-bottom: black 1.5pt solid; padding-bottom: 1.2pt; text-align: justify; font-weight: bold"&gt;Weighted Average Amortization Period (In months)&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" rowspan="3" style="padding-bottom: 1.2pt; text-align: justify; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: justify; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="padding-bottom: 1.2pt; text-align: justify; font-weight: bold"&gt;Gross&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: justify; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="padding-bottom: 1.2pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td rowspan="3" style="padding-bottom: 1.2pt; text-align: justify; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" rowspan="3" style="border-bottom: black 1.5pt solid; padding-bottom: 1.2pt; text-align: justify; font-weight: bold"&gt;Impairment Loss&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" rowspan="3" style="padding-bottom: 1.2pt; text-align: justify; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td rowspan="3" style="padding-bottom: 1.2pt; text-align: justify; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" rowspan="3" style="border-bottom: black 1.5pt solid; padding-bottom: 1.2pt; text-align: justify; font-weight: bold"&gt;Transfer to Held for Sale&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" rowspan="3" style="padding-bottom: 1.2pt; text-align: justify; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td rowspan="3" style="padding-bottom: 1.2pt; text-align: justify; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" rowspan="3" style="border-bottom: black 1.5pt solid; text-align: justify; font-weight: bold"&gt;Net&amp;#160;Carrying&amp;#160;Value&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" rowspan="3" style="padding-bottom: 1.2pt; text-align: justify; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: justify; font-weight: bold"&gt;Carrying&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: justify; font-weight: bold"&gt;Accumulated&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: justify; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; padding-bottom: 1.2pt; text-align: justify; font-weight: bold"&gt;Amount&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: justify; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: justify; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="padding-bottom: 1.2pt; text-align: justify; font-weight: bold"&gt;Amortization&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: justify; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify; font-style: italic; font-weight: bold; text-indent: 18pt"&gt;Indefinite Lived Intangible:&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;Trade name&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: justify"&gt;Indefinite&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;8,700,000&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#151;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#151;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#151;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;8,700,000&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: justify; font-style: italic; font-weight: bold; text-indent: 18pt"&gt;Definite Lived Intangibles:&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="width: 28%; text-align: justify"&gt;Patent litigation&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: justify"&gt;84&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: justify"&gt;8,195,037&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: justify"&gt;1,709,382&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: justify"&gt;&amp;#151;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: justify"&gt;&amp;#151;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: justify"&gt;6,485,655&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: justify"&gt;Patents&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;120&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;10,974,393&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;1,034,124&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;5,649,160&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;3,500,000&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;795,109&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;Acquired technology&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;60&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;7,270,000&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;2,102,250&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#151;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#151;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;5,167,750&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: justify"&gt;Customer relationships&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;60-72&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;12,850,000&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;3,509,375&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#151;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#151;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;9,340,625&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify"&gt;Software&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;36&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;2,095,706&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;2,095,706&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#151;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#151;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#151;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;Non-compete agreements&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;36&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;212,000&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;212,000&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#151;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#151;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#151;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: justify"&gt;Trade names&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: justify"&gt;24&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; padding-bottom: 1.2pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; padding-bottom: 1.2pt; text-align: justify"&gt;44,000&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; padding-bottom: 1.2pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; padding-bottom: 1.2pt; text-align: justify"&gt;44,000&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; padding-bottom: 1.2pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; padding-bottom: 1.2pt; text-align: justify"&gt;&amp;#151;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; padding-bottom: 1.2pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; padding-bottom: 1.2pt; text-align: justify"&gt;&amp;#151;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: justify"&gt;&amp;#151;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.4pt; text-align: justify"&gt;Total intangibles&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.4pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.4pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.4pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.4pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.4pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; padding-bottom: 2.4pt; text-align: justify"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; padding-bottom: 2.4pt; text-align: justify"&gt;50,341,136&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.4pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.4pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; padding-bottom: 2.4pt; text-align: justify"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; padding-bottom: 2.4pt; text-align: justify"&gt;10,702,837&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.4pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.4pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; padding-bottom: 2.4pt; text-align: justify"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; padding-bottom: 2.4pt; text-align: justify"&gt;5,649,160&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.4pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.4pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; padding-bottom: 2.4pt; text-align: justify"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; padding-bottom: 2.4pt; text-align: justify"&gt;3,500,000&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.4pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.4pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: justify"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: justify"&gt;30,489,139&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.4pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="padding-bottom: 1.2pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: justify; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="11" style="border-bottom: black 1.5pt solid; text-align: justify; font-weight: bold"&gt;As&amp;#160;of&amp;#160;February 29, 2012&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: justify; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; padding-bottom: 1.2pt; text-align: justify; font-weight: bold"&gt;Weighted Average Amortization Period (In months)&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: justify; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: justify; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; padding-bottom: 1.2pt"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Gross&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Carrying&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Amount&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: justify; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: justify; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; padding-bottom: 1.2pt"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Accumulated&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Amortization&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: justify; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: justify; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1.5pt solid; text-align: justify; font-weight: bold"&gt;Net&amp;#160;Carrying&amp;#160;Value&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify; font-style: italic; font-weight: bold"&gt;Indefinite Lived Intangible:&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&amp;#160;&amp;#160;Trade name&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: justify"&gt;Indefinite&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;8,700,000&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#151;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;8,700,000&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: justify; font-style: italic; font-weight: bold"&gt;Definite Lived Intangibles:&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="width: 52%; text-align: justify"&gt;&amp;#160;&amp;#160;&amp;#160;Patent litigation&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: justify"&gt;84&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: justify"&gt;5,471,107&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: justify"&gt;950,150&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: justify"&gt;4,520,957&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&amp;#160;&amp;#160;Patents&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;120&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;6,340,300&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;292,297&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;6,048,003&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&amp;#160;&amp;#160;Acquired technology&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;60&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;7,270,000&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;1,011,750&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;6,258,250&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&amp;#160;&amp;#160;Customer relationships&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;60-72&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;12,850,000&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;1,605,625&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;11,244,375&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&amp;#160;&amp;#160;Software&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;36&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;2,095,706&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;2,095,706&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#151;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&amp;#160;&amp;#160;Non-compete agreements&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;36&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;212,000&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;185,500&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;26,500&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: justify"&gt;&amp;#160;&amp;#160;&amp;#160;Trade names&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: justify"&gt;24&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; padding-bottom: 1.2pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; padding-bottom: 1.2pt; text-align: justify"&gt;44,000&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; padding-bottom: 1.2pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; padding-bottom: 1.2pt; text-align: justify"&gt;44,000&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.2pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: justify"&gt;&amp;#151;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.4pt; text-align: justify"&gt;Total intangibles&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.4pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.4pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.4pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.4pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.4pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; padding-bottom: 2.4pt; text-align: justify"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; padding-bottom: 2.4pt; text-align: justify"&gt;42,983,113&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.4pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.4pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; padding-bottom: 2.4pt; text-align: justify"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; padding-bottom: 2.4pt; text-align: justify"&gt;6,185,028&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.4pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.4pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: justify"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: justify"&gt;36,798,085&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.4pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</augt:ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTableTextBlock>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="D2013Q2YTD">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Amortization in future fiscal periods is expected&#13;to be as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 60%; text-align: justify"&gt;Remainder of 2013&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 3%; text-align: justify"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 35%; text-align: justify"&gt;1,411,869&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify"&gt;2014&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: justify"&gt;5,247,475&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: justify"&gt;2015&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: justify"&gt;5,163,725&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify"&gt;2016&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: justify"&gt;5,014,517&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: justify"&gt;2017&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: justify"&gt;2,997,523&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: justify"&gt;Thereafter&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: justify"&gt;2,054,030&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.2pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.4pt; text-align: justify"&gt;Total&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.4pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: justify"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: justify"&gt;21,789,139&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.4pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="I2012" unitRef="USD" decimals="0">26000500</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="I2013Q2" unitRef="USD" decimals="0">39661</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="AsOf2012-08-31" unitRef="USD" decimals="0">10999890</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements contextRef="From2012-09-01to2012-11-30" unitRef="USD" decimals="0">-3621056</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements contextRef="D2013Q2YTD" unitRef="USD" decimals="0">-13761109</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="From2012-09-01to2012-11-30" unitRef="USD" decimals="0">-7339173</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="D2013Q2YTD" unitRef="USD" decimals="0">-12199730</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:BusinessAcquisitionsProFormaRevenue contextRef="D2012Q2YTD" unitRef="USD" decimals="0">11851321</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss contextRef="D2012Q2YTD" unitRef="USD" decimals="0">-21985225</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <augt:BusinessAcquisitionProFormaWeightedAverageCommonShares contextRef="D2012Q2YTD" unitRef="Shares" decimals="INF">82905010</augt:BusinessAcquisitionProFormaWeightedAverageCommonShares>
    <augt:BusinessAcquisitionProFormaEarningsPerShareBasicDiluted contextRef="D2012Q2YTD" unitRef="USDPerShare" decimals="INF">-0.27</augt:BusinessAcquisitionProFormaEarningsPerShareBasicDiluted>
    <augt:NumberOfIssuedPatents contextRef="D2013Q2YTD" unitRef="Integer" decimals="INF">13</augt:NumberOfIssuedPatents>
    <augt:NumberOfPendingUSAndForeignPatentApplications contextRef="D2013Q2YTD" unitRef="Integer" decimals="INF">80</augt:NumberOfPendingUSAndForeignPatentApplications>
    <us-gaap:NumberOfReportableSegments contextRef="D2013Q2YTD" unitRef="Integer" decimals="INF">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="I2012" unitRef="USD" decimals="0">-72533071</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="I2013Q2" unitRef="USD" decimals="0">-87362012</us-gaap:RetainedEarningsAccumulatedDeficit>
    <augt:WorkingCapital contextRef="I2013Q2" unitRef="USD" decimals="0">3</augt:WorkingCapital>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="I2013Q2" unitRef="USD" decimals="0">2</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:RestructuringAndRelatedCostExpectedCost contextRef="D2013Q2YTD" unitRef="USD" decimals="0">0</us-gaap:RestructuringAndRelatedCostExpectedCost>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="D2013Q2YTD" unitRef="Shares" decimals="INF">8.5</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="D2013Q2YTD" unitRef="USD" decimals="0">6</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <augt:CostRelatedWithStockIssuedToPublic contextRef="D2013Q2YTD" unitRef="USD" decimals="0">1</augt:CostRelatedWithStockIssuedToPublic>
    <augt:CommonStockIssuedForPublicOfferingsPerShare contextRef="D2013Q2YTD" unitRef="USDPerShare" decimals="INF">0.80</augt:CommonStockIssuedForPublicOfferingsPerShare>
    <us-gaap:AvailableforsaleSecuritiesSoldAtPar contextRef="D2013Q2YTD" unitRef="USD" decimals="0">75</us-gaap:AvailableforsaleSecuritiesSoldAtPar>
    <augt:UnsoldSecuritiesRemaining contextRef="D2013Q2YTD" unitRef="USD" decimals="0">48</augt:UnsoldSecuritiesRemaining>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2012-03-01to2012-11-30_WarrantMember" unitRef="Shares" decimals="INF">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2012-03-01to2012-11-30_StockOptionsMember" unitRef="Shares" decimals="INF">2200000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2012-09-01to2012-11-30_StockOptionsMember" unitRef="Pure" decimals="INF">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2011-09-01to2011-11-30_StockOptionsMember" unitRef="Pure" decimals="INF">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2012-03-01to2012-11-30_StockOptionsMember11985712" unitRef="Pure" decimals="INF">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2011-03-01to2011-11-30_StockOptionsMember" unitRef="Pure" decimals="INF">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2012-09-01to2012-11-30_WarrantMember" unitRef="Pure" decimals="INF">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2011-09-01to2011-11-30_WarrantMember" unitRef="Pure" decimals="INF">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2012-03-01to2012-11-30_WarrantMember11985712" unitRef="Pure" decimals="INF">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2011-03-01to2011-11-30_WarrantMember" unitRef="Pure" decimals="INF">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2012-09-01to2012-11-30_StockOptionsMember">P3Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2011-09-01to2011-11-30_StockOptionsMember">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2012-03-01to2012-11-30_StockOptionsMember11985712">P3Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2011-03-01to2011-11-30_StockOptionsMember">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2012-09-01to2012-11-30_WarrantMember">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2011-09-01to2011-11-30_WarrantMember">P3Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2012-03-01to2012-11-30_WarrantMember11985712">P4Y9M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2011-03-01to2011-11-30_WarrantMember">P3Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate contextRef="From2012-09-01to2012-11-30_StockOptionsMember" unitRef="Pure" decimals="INF">0.6500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate contextRef="From2011-09-01to2011-11-30_StockOptionsMember" unitRef="Pure" decimals="INF">0.7770</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate contextRef="From2012-03-01to2012-11-30_StockOptionsMember11985712" unitRef="Pure" decimals="INF">0.6238</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate contextRef="From2011-03-01to2011-11-30_StockOptionsMember" unitRef="Pure" decimals="INF">0.7770</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate contextRef="From2012-09-01to2012-11-30_WarrantMember" unitRef="Pure" decimals="INF">0.6500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate contextRef="From2011-09-01to2011-11-30_WarrantMember" unitRef="Pure" decimals="INF">0.8132</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate contextRef="From2012-03-01to2012-11-30_WarrantMember11985712" unitRef="Pure" decimals="INF">0.6437</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate contextRef="From2011-03-01to2011-11-30_WarrantMember" unitRef="Pure" decimals="INF">0.7780</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2012-09-01to2012-11-30_StockOptionsMember" unitRef="Pure" decimals="INF">0.0043</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2011-09-01to2011-11-30_StockOptionsMember" unitRef="Pure" decimals="INF">0.0040</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2012-03-01to2012-11-30_StockOptionsMember11985712" unitRef="Pure" decimals="INF">0.0044</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2011-03-01to2011-11-30_StockOptionsMember" unitRef="Pure" decimals="INF">0.0040</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2012-09-01to2012-11-30_WarrantMember" unitRef="Pure" decimals="INF">0.0062</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2011-09-01to2011-11-30_WarrantMember" unitRef="Pure" decimals="INF">0.0040</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2012-03-01to2012-11-30_WarrantMember11985712" unitRef="Pure" decimals="INF">0.0059</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2011-03-01to2011-11-30_WarrantMember" unitRef="Pure" decimals="INF">0.0040</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2012-09-01to2012-11-30_StockOptionsMember" unitRef="USD" decimals="0">1187253</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2011-09-01to2011-11-30_StockOptionsMember" unitRef="USD" decimals="0">2316000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2012-03-01to2012-11-30_StockOptionsMember11985712" unitRef="USD" decimals="0">3679444</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2011-03-01to2011-11-30_StockOptionsMember" unitRef="USD" decimals="0">4670498</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2012-09-01to2012-11-30_SellingAndMarketingExpenseMember_StockOptionsMember" unitRef="USD" decimals="0">379756</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2011-09-01to2011-11-30_SellingAndMarketingExpenseMember_StockOptionsMember" unitRef="USD" decimals="0">1043590</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2012-03-01to2012-11-30_SellingAndMarketingExpenseMember_StockOptionsMember" unitRef="USD" decimals="0">1407393</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2011-03-01to2011-11-30_SellingAndMarketingExpenseMember_StockOptionsMember" unitRef="USD" decimals="0">2104527</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2012-09-01to2012-11-30_TechnologyAndDevelopmentMember_StockOptionsMember" unitRef="USD" decimals="0">272621</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2011-09-01to2011-11-30_TechnologyAndDevelopmentMember_StockOptionsMember" unitRef="USD" decimals="0">425449</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2012-03-01to2012-11-30_TechnologyAndDevelopmentMember_StockOptionsMember" unitRef="USD" decimals="0">882591</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2011-03-01to2011-11-30_TechnologyAndDevelopmentMember_StockOptionsMember" unitRef="USD" decimals="0">857970</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2012-09-01to2012-11-30_GeneralAndAdministrativeExpenseMember_StockOptionsMember" unitRef="USD" decimals="0">534876</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2011-09-01to2011-11-30_GeneralAndAdministrativeExpenseMember_StockOptionsMember" unitRef="USD" decimals="0">846961</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2012-03-01to2012-11-30_GeneralAndAdministrativeExpenseMember_StockOptionsMember" unitRef="USD" decimals="0">1389460</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2011-03-01to2011-11-30_GeneralAndAdministrativeExpenseMember_StockOptionsMember" unitRef="USD" decimals="0">1708001</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2012-09-01to2012-11-30_WarrantMember" unitRef="USD" decimals="0">188849</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2011-09-01to2011-11-30_WarrantMember" unitRef="USD" decimals="0">1193943</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2012-03-01to2012-11-30_WarrantMember11985712" unitRef="USD" decimals="0">622915</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2011-03-01to2011-11-30_WarrantMember" unitRef="USD" decimals="0">2339790</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="I2012_StockOptionsMember" unitRef="Shares" decimals="INF">20153219</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2012-11-30_StockOptionsMember" unitRef="Shares" decimals="INF">18466792</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2012-02-29_WarrantMember" unitRef="Shares" decimals="INF">10787641</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2012-11-30_WarrantMember" unitRef="Shares" decimals="INF">12975140</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2012-03-01to2012-11-30_StockOptionsMember11985712" unitRef="Shares" decimals="INF">2850268</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2012-03-01to2012-11-30_WarrantMember11985712" unitRef="Shares" decimals="INF">3187499</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2012-03-01to2012-11-30_StockOptionsMember11985712" unitRef="Shares" decimals="INF">-572092</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2012-03-01to2012-11-30_WarrantMember11985712" unitRef="Shares" decimals="INF">-1000000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod contextRef="From2012-03-01to2012-11-30_StockOptionsMember11985712" unitRef="Shares" decimals="INF">-3964603</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod contextRef="From2012-03-01to2012-11-30_WarrantMember11985712" unitRef="Shares" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="AsOf2012-11-30_StockOptionsMember" unitRef="Shares" decimals="INF">17570483</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="AsOf2012-11-30_StockOptionsMember" unitRef="Shares" decimals="INF">12491061</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="AsOf2012-11-30_WarrantMember" unitRef="Shares" decimals="INF">12312642</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="I2012_StockOptionsMember" unitRef="USDPerShare" decimals="INF">2.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2012-11-30_StockOptionsMember" unitRef="USDPerShare" decimals="INF">2.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2012-02-29_WarrantMember" unitRef="USDPerShare" decimals="INF">1.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2012-11-30_WarrantMember" unitRef="USDPerShare" decimals="INF">1.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2012-03-01to2012-11-30_StockOptionsMember11985712" unitRef="USDPerShare" decimals="INF">1.48</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2012-03-01to2012-11-30_WarrantMember11985712" unitRef="USDPerShare" decimals="INF">1.17</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="From2012-03-01to2012-11-30_StockOptionsMember11985712" unitRef="USDPerShare" decimals="INF">0.53</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="From2012-03-01to2012-11-30_WarrantMember11985712" unitRef="USDPerShare" decimals="INF">1</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice contextRef="From2012-03-01to2012-11-30_StockOptionsMember11985712" unitRef="USDPerShare" decimals="INF">2.41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice contextRef="From2012-03-01to2012-11-30_WarrantMember11985712" unitRef="USDPerShare" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice contextRef="AsOf2012-11-30_StockOptionsMember" unitRef="USDPerShare" decimals="INF">2.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice contextRef="AsOf2012-11-30_WarrantMember" unitRef="USDPerShare" decimals="INF">1.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="AsOf2012-11-30_StockOptionsMember" unitRef="USDPerShare" decimals="INF">1.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="AsOf2012-11-30_WarrantMember" unitRef="USDPerShare" decimals="INF">1.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <augt:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3 contextRef="I2012_StockOptionsMember">P3Y9M17D</augt:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3>
    <augt:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3 contextRef="AsOf2012-11-30_StockOptionsMember">P3Y2M29D</augt:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3>
    <augt:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3 contextRef="AsOf2012-02-29_WarrantMember">P2Y9M7D</augt:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3>
    <augt:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3 contextRef="AsOf2012-11-30_WarrantMember">P2Y9M3D</augt:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3>
    <augt:GrantedAverageRemainingContractualTerm contextRef="From2012-03-01to2012-11-30_StockOptionsMember11985712">P0Y</augt:GrantedAverageRemainingContractualTerm>
    <augt:GrantedAverageRemainingContractualTerm contextRef="From2012-03-01to2012-11-30_WarrantMember11985712">P0Y</augt:GrantedAverageRemainingContractualTerm>
    <augt:ExercisedAverageRemainingContractualTerm contextRef="From2012-03-01to2012-11-30_StockOptionsMember11985712">P0Y</augt:ExercisedAverageRemainingContractualTerm>
    <augt:ExercisedAverageRemainingContractualTerm contextRef="From2012-03-01to2012-11-30_WarrantMember11985712">P0Y</augt:ExercisedAverageRemainingContractualTerm>
    <augt:ForfeitedCancelledAndExpiredAverageRemainingContractualTerm contextRef="From2012-03-01to2012-11-30_StockOptionsMember11985712">P0Y</augt:ForfeitedCancelledAndExpiredAverageRemainingContractualTerm>
    <augt:ForfeitedCancelledAndExpiredAverageRemainingContractualTerm contextRef="From2012-03-01to2012-11-30_WarrantMember11985712">P0Y</augt:ForfeitedCancelledAndExpiredAverageRemainingContractualTerm>
    <augt:OptionsVestedAndExpectedToVestAtNovemberAverageRemainingContractualTerm contextRef="AsOf2012-11-30_StockOptionsMember">P3Y2M5D</augt:OptionsVestedAndExpectedToVestAtNovemberAverageRemainingContractualTerm>
    <augt:OptionsExercisableAverageRemainingContractualTerm contextRef="AsOf2012-11-30_StockOptionsMember">P2Y102M</augt:OptionsExercisableAverageRemainingContractualTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber contextRef="AsOf2012-11-30_WarrantMember" unitRef="Shares" decimals="INF">12932640</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <augt:WarrantsVestedAndExpectedToVestAverageRemainingContractualTerm contextRef="AsOf2012-11-30_WarrantMember">P2Y11M26D</augt:WarrantsVestedAndExpectedToVestAverageRemainingContractualTerm>
    <augt:WarrantsExercisableAndOutstandingAverageRemainingContractualTerm contextRef="AsOf2012-11-30_WarrantMember">P2Y8M8D</augt:WarrantsExercisableAndOutstandingAverageRemainingContractualTerm>
    <augt:StockOptionsAndRestrictedShares contextRef="AsOf2012-11-30_StockOptionsMember" unitRef="Shares" decimals="INF">13056707</augt:StockOptionsAndRestrictedShares>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="AsOf2012-11-30_StockOptionsMember" unitRef="USD" decimals="0">4800000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="AsOf2012-11-30_WarrantMember" unitRef="USD" decimals="0">300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <augt:UnrecognizedSharebasedPaymentExpenseExpectedToBeRecognized contextRef="From2012-03-01to2012-11-30_StockOptionsMember11985712">P2Y</augt:UnrecognizedSharebasedPaymentExpenseExpectedToBeRecognized>
    <augt:UnrecognizedSharebasedPaymentExpenseExpectedToBeRecognized contextRef="From2012-03-01to2012-11-30_WarrantMember11985712">P2Y2M12D</augt:UnrecognizedSharebasedPaymentExpenseExpectedToBeRecognized>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="AsOf2012-11-30_StockOptionsMember" unitRef="USD" decimals="0">90000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="AsOf2012-11-30_WarrantMember" unitRef="USD" decimals="0">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <augt:AggregateIntrinsicValueOfExercisableOptionsPerShare contextRef="AsOf2012-11-30_StockOptionsMember" unitRef="USDPerShare" decimals="INF">0.61</augt:AggregateIntrinsicValueOfExercisableOptionsPerShare>
    <augt:AggregateIntrinsicValueOfExercisableOptionsPerShare contextRef="AsOf2012-11-30_WarrantMember" unitRef="USDPerShare" decimals="INF">0.61</augt:AggregateIntrinsicValueOfExercisableOptionsPerShare>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit contextRef="From2012-03-01to2012-11-30_StockOptionsMember11985712" unitRef="USDPerShare" decimals="INF">.25</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit contextRef="From2012-03-01to2012-11-30_WarrantMember11985712" unitRef="USDPerShare" decimals="INF">0.90</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit contextRef="From2012-03-01to2012-11-30_StockOptionsMember11985712" unitRef="USDPerShare" decimals="INF">4.10</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit contextRef="From2012-03-01to2012-11-30_WarrantMember11985712" unitRef="USDPerShare" decimals="INF">4.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <augt:AggregateIntrinsicValueOfOptionsExercised contextRef="From2012-03-01to2012-11-30_StockOptionsMember11985712" unitRef="USD" decimals="0">800000</augt:AggregateIntrinsicValueOfOptionsExercised>
    <augt:AggregateIntrinsicValueOfOptionsExercised contextRef="From2012-03-01to2012-11-30_WarrantMember11985712" unitRef="USD" decimals="0">800000</augt:AggregateIntrinsicValueOfOptionsExercised>
    <augt:BusinessAcquisitionContingentConsiderationAtFairValuePeriodEnd contextRef="I2012" unitRef="USD" decimals="0">26000500</augt:BusinessAcquisitionContingentConsiderationAtFairValuePeriodEnd>
    <augt:BusinessAcquisitionContingentConsiderationAtFairValuePeriodEnd contextRef="I2013Q2" unitRef="USD" decimals="0">39661</augt:BusinessAcquisitionContingentConsiderationAtFairValuePeriodEnd>
    <us-gaap:BusinessAcquisitionCostOfAcquiredEntityPurchasePrice contextRef="I2013Q1_HipcricketIncMember_AcquisitionRelatedContingentConsiderationMember" unitRef="USD" decimals="INF">6280000</us-gaap:BusinessAcquisitionCostOfAcquiredEntityPurchasePrice>
    <us-gaap:BusinessAcquisitionCostOfAcquiredEntityCashPaid contextRef="I2013Q1_HipcricketIncMember_AcquisitionRelatedContingentConsiderationMember" unitRef="USD" decimals="-5">300000</us-gaap:BusinessAcquisitionCostOfAcquiredEntityCashPaid>
    <us-gaap:BusinessAcquisitionCostOfAcquiredEntityEquityInterestsIssuedAndIssuable contextRef="I2013Q1_HipcricketIncMember_AcquisitionRelatedContingentConsiderationMember" unitRef="USD" decimals="INF">3550000</us-gaap:BusinessAcquisitionCostOfAcquiredEntityEquityInterestsIssuedAndIssuable>
    <us-gaap:SharePrice contextRef="I2013Q1_HipcricketIncMember_AcquisitionRelatedContingentConsiderationMember" unitRef="USDPerShare" decimals="INF">3.10</us-gaap:SharePrice>
    <augt:BusinessAcquisitionCostOfAcquiredEntityLiabilitiesIncurredExcludingContingentConsideration contextRef="I2013Q1_HipcricketIncMember_AcquisitionRelatedContingentConsiderationMember" unitRef="USD" decimals="-5">100000</augt:BusinessAcquisitionCostOfAcquiredEntityLiabilitiesIncurredExcludingContingentConsideration>
    <augt:BusinessAcquisitionContingentConsiderationSellerTaxLiabilities contextRef="I2013Q1_HipcricketIncMember_AcquisitionRelatedContingentConsiderationMember" unitRef="USD" decimals="-5">200000</augt:BusinessAcquisitionContingentConsiderationSellerTaxLiabilities>
    <us-gaap:BusinessAcquisitionContingentConsiderationAtFairValue contextRef="I2013Q1_HipcricketIncMember_AcquisitionRelatedContingentConsiderationMember" unitRef="USD" decimals="INF">2330000</us-gaap:BusinessAcquisitionContingentConsiderationAtFairValue>
    <augt:BusinessAcquisitionContingentConsiderationAggregateLiability contextRef="I2013Q1_HipcricketIncMember_AcquisitionRelatedContingentConsiderationMember" unitRef="USD" decimals="INF">2520000</augt:BusinessAcquisitionContingentConsiderationAggregateLiability>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock contextRef="D2013Q2YTD">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 10pt"&gt;The Company reviews goodwill for&#13;impairment annually as of the first day of its fourth fiscal quarter, generally December 1&lt;sup&gt;st&lt;/sup&gt;, and whenever events or&#13;changes in circumstances indicate the carrying value of goodwill may not be recoverable. The goodwill impairment test involves&#13;a two-step process. In the first step, we compare the fair value of each reporting unit to its carrying value. If the fair value&#13;of the reporting unit exceeds its carrying value, goodwill is not impaired and no further testing is required. If the fair value&#13;of the reporting unit is less than the carrying value, the Company must perform the second step of the impairment test to measure&#13;the amount of impairment loss, if any. If the implied fair value of the reporting unit's goodwill is less than the carrying value,&#13;the difference is recorded as an impairment loss.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 22.5pt"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 10pt"&gt;The Company estimates the fair value&#13;of its reporting units using a weighting of fair values derived most significantly from the income approach and, to a lesser extent,&#13;the market approach. Under the income approach, the Company calculates the fair value of a reporting unit based on the present&#13;value of estimated future cash flows. Cash flow projections are based on management's estimates of revenue growth rates and operating&#13;margins, taking into consideration industry and market conditions. The discount rate used is based on the weighted-average cost&#13;of capital adjusted for the relevant risk associated with business-specific characteristics and the uncertainty related to the&#13;business's ability to execute on the projected cash flows. The market approach estimates fair value based on market multiples&#13;of revenue and earnings derived from comparable publicly-traded companies with similar operating and investment characteristics&#13;as the reporting unit. The weighting of the fair value derived from the market approach ranges from 0% to 50% depending on the&#13;level of comparability of these publicly-traded companies to the reporting unit. When market comparables are not meaningful or&#13;not available, the Company may estimate the fair value of a reporting unit using only the income approach.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 10pt"&gt;In order to assess the reasonableness&#13;of the calculated fair values of its reporting units, the Company also compares the sum of the reporting units' fair values to&#13;the Company&amp;#146;s market capitalization and calculates an implied control premium (the excess of the sum of the reporting units'&#13;fair values over the market capitalization). The Company evaluates the control premium by comparing it to control premiums of&#13;recent comparable market transactions. If the implied control premium is not reasonable in light of these recent transactions,&#13;the Company will reevaluate its fair value estimates of the reporting units by adjusting the discount rates and/or other assumptions.&#13;As a result, when there is a significant decline in the Company&amp;#146;s stock price, as occurred during fiscal 2012, this reevaluation&#13;could correlate to lower estimated fair values for certain or all of the Company&amp;#146;s reporting units.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;The Company has a single operating segment, however there two reporting&#13;units for purposes of its goodwill impairment assessment, and all of the recorded goodwill is attributed to the Mobile Marketing&#13;and Advertising reporting unit, which generates substantially all of the revenues and expenses of the Company. The second reporting&#13;unit represents the Intellectual Property reporting unit, which does not contain any attributed goodwill&lt;/font&gt;.&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <augt:StockOptionsandRestrictedSharesAuthorized contextRef="AsOf2012-11-30_StockOptionsMember" unitRef="Shares" decimals="INF">15000000</augt:StockOptionsandRestrictedSharesAuthorized>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="D2013Q2YTD">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;On May 24, 2012, the Company acquired all of the common stock and&#13;all of the preferred stock of Geos Communications IP Holdings, Inc. (&amp;#147;Geos IP&amp;#148;). The fair value of the consideration&#13;given for the acquisition of the Geos IP stock was $4.2 million, which included $355,000 in cash and $3.8 million in Augme&amp;#146;s&#13;common stock (1,860,465 shares at a price of $2.05 per share). The Company is indemnified against certain losses resulting from&#13;breaches of any representation, warranty, covenant or agreement of Geos IP. In order to secure payment of any loss, the approximate&#13;1.9 million shares of Augme&amp;#146;s common stock will be held for the benefit of the sellers in escrow for a period of up to 14&#13;months following the closing date of the acquisition.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The Company&amp;#146;s former Chief Executive Officer, Paul Arena,&#13;was a director of Geos Communications, Inc. (the &amp;#147;Parent&amp;#148;), which is the parent company of Geos IP, until March 8,&#13;2010 and is an owner of the Parent&amp;#146;s common stock and options to purchase the Parent&amp;#146;s common stock. The Company&amp;#146;s&#13;former director, Ernest W. Purcell, and Phillip C. Rapp, Jr., the Company&amp;#146;s former Executive Vice President of Strategic&#13;Planning, are preferred stockholders of Geos IP. After the indemnification period is concluded, Mr. Purcell will receive 25,492&#13;shares of the Company&amp;#146;s common stock and Mr. Rapp will receive 33,468 shares of the Company&amp;#146;s common stock as consideration&#13;in the transaction. Mr. Arena did not receive any consideration in the transaction.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;In September 2012, the Company issued a note payable in the amount&#13;of $200,000 to Ernest W. Purcell, a former director. The Company also issued to Mr. Purcell warrants to purchase 50,000 shares&#13;of common stock of the Company. The loan, which was used for working capital, was paid in full in October 2012.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:TradingGainsLosses contextRef="From2011-09-01to2011-11-30" unitRef="USD" decimals="0">4200000</us-gaap:TradingGainsLosses>
    <augt:CashValueConsideration contextRef="From2011-09-01to2011-11-30" unitRef="USD" decimals="0">355000</augt:CashValueConsideration>
    <augt:StockValueConsideration contextRef="From2011-09-01to2011-11-30" unitRef="Shares" decimals="INF">3800000</augt:StockValueConsideration>
    <augt:SharesAmount contextRef="From2011-09-01to2011-11-30" unitRef="Shares" decimals="INF">-1860465</augt:SharesAmount>
    <augt:SharesHeldInSecurity contextRef="From2011-09-01to2011-11-30" unitRef="Shares" decimals="INF">1900000</augt:SharesHeldInSecurity>
    <augt:EscrowPeriod contextRef="From2011-09-01to2011-11-30">P14Y</augt:EscrowPeriod>
    <augt:SharesProvidedPastIndemnificationToOfficer contextRef="From2011-09-01to2011-11-30" unitRef="Shares" decimals="INF">25492</augt:SharesProvidedPastIndemnificationToOfficer>
    <augt:SharesProvidedPastIndemnificationToDirector contextRef="From2011-09-01to2011-11-30" unitRef="Shares" decimals="INF">33468</augt:SharesProvidedPastIndemnificationToDirector>
    <augt:NotePayableToDirectorAmount contextRef="From2011-09-01to2011-11-30" unitRef="Shares" decimals="INF">200000</augt:NotePayableToDirectorAmount>
    <augt:Warrants contextRef="From2011-09-01to2011-11-30" unitRef="Shares" decimals="INF">50000</augt:Warrants>
    <augt:SharesConsiderationValue contextRef="From2011-09-01to2011-11-30" unitRef="USDPerShare" decimals="INF">2.05</augt:SharesConsiderationValue>
    <augt:ReclassificationOfIntangibleAssetsFromLongtermToHeldForSale contextRef="D2012Q2YTD" unitRef="USD" xsi:nil="true" />
    <augt:ReclassificationOfIntangibleAssetsFromLongtermToHeldForSale contextRef="D2013Q2YTD" unitRef="USD" decimals="0">3500000</augt:ReclassificationOfIntangibleAssetsFromLongtermToHeldForSale>
</xbrli:xbrl>
